

Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKSSAAWDETLDDKFTYELYQQLNDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKSSAAWDETLDDKFTYELYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188
Db 181 QESLRSKE 188

RESULT 2

AAV69484 ID AAV69484 standard; protein; 188 AA.

AAV69484; AC

DT 03-JUL-2000 (first entry)

DE Amino acid sequence of human interferon-alpha2B.

KW Human; interferon-alpha2B; IFN-M gene; chicken magnum; transgenic avian;
KM oviduct; viral particle; deleterious mutation; avian egg.

OS Synthetic.
OS Homo sapiens.
OS Gallus sp.

PN WO200011151-A2.

PD 02-MAR-2000.

PF 25-AUG-1999; 99WO-US019393.

PR 25-AUG-1998; 98US-00139902.

PA (UYGE-) UNIV GEORGIA RES FOUND INC.

PI Ivarie R, Harvey AJ, Murphy GF, Rapp JC;

DR WPI; 2000-237645/20.

DR N-PSDB; AAZ99577, AAZ99578.

PT Direct oviduct transgenesis of avians useful for expression of exogenous
PT proteins in eggs and for assessing suitability of expression cassettes or
PT to screen a preparation of viral particles for deleterious mutations.

PS Example 1; Page 53-54; 54pp; English.

XX The present sequence represents human interferon-alpha2B polypeptide. The
CC polynucleotide was modified with codons for the chicken magnum, and used
CC to construct a vector for use in the method of the invention. The
CC specification describes a method for preparing a transgenic avian which
CC expresses an exogenous protein substantially only in its oviduct. The
CC method comprises delivering a nucleic acid expression cassette directly
CC to the oviduct of an immature avian, where the nucleic acid expression
CC cassette comprises a promoter active in the avian oviduct, and a nucleic
CC acid sequence coding for an exogenous protein, linked to the promoter.
CC The method can be used to screen a preparation of viral particles for a
CC deleterious mutations. It can also be used to test the suitability of a
CC transgene for expression in an avian oviduct or for secretion of its
CC expression product into the lumen of the oviduct and into eggs of an
CC avian

XX SQ Sequence 188 AA;

Query Match 100.0%; Score 960; DB 3; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKSSAAWDETLDDKFTYELYQQLNDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQQIFNLFSTKSSAAWDETLDDKFTYELYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180

QY 181 QESLRSKE 188

Db 181 QESLRSKE 188

RESULT 3

AAE15828 ID AAE15828 standard; protein; 188 AA.

AAE15828; AC

DT 26-MAR-2002 (first entry)

DE Human interferon (IFN) alpha 2 protein.

KW Human; vaccine; immunostimulatory molecule; interferon; IFN; therapy;
KM antigen presentation; vaccine; tumorigenesis; cancer; cytostatic;
KM antitumour; antibacterial; virucide; fungicide; protozoacide.

OS Homo sapiens.

PN WO200188097-A1.

PD 22-NOV-2001.

PF 17-MAY-2001; 2001WO-AU000565.

PR 17-MAY-2000; 2000AU-00007553.

PA (MONU) UNIV MONASH.

PI Ralph SJ;

DR WPI; 2002-082990/11.

DR N-PSDB; AAD25508.

PT New composition, useful for treatment and/or prophylaxis of cancer and
PT tumor, comprises immunostimulatory molecule and animal cells cultured in
PT presence of interferon to enhance antigen presenting function of the
PT cells.

PS Claim 45; Page 96-97; 127pp; English.

XX The present invention relates to a composition of matter comprising an
CC immunostimulatory molecule and animal cells cultured in the presence of
CC at least one interferon (IFN) for a time and under conditions sufficient
CC to enhance the antigen presenting function of the cells. The invention is
CC used as vaccine. The composition is useful for treatment and/or
CC prophylaxis of tumorigenesis, cancer, viral, bacterial, fungal and
CC protozoal infections. The composition which comprises the soluble
CC immunostimulatory molecule and the cultured animal cells is administered
CC separately, sequentially or simultaneously to the patient. The present
CC sequence is human IFN alpha 2 protein

SEQ	Sequence 188 AA;	
Query Match	100.0%;	Score 960; DB 5; Length 188;
Best Local Similarity	100.0%;	Pred. No. 3,8e-90;
Matches 188;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0
QY	1	MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTLMMLAQMRRISLFSCLKDRHDFG 60
Db	1	MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTLMMLAQMRRISLFSCLKDRHDFG 60
QY	61	FPOEEFGNFOKAETIPVLHEMIQOIFNLFSTKDSAAWDETLIDKFYTELYQQLNDLEA 12
Db	61	FPOEEFGNFOKAETIPVLHEMIQOIFNLFSTKDSAAWDETLIDKFYTELYQQLNDLEA 12
QY	121	CVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVYRAEIMRSFSLSTNL 18
Db	121	CVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVYRAEIMRSFSLSTNL 18
QY	181	QESLRKE 188
Db	181	QESLRKE 188
RESULT 4		
AAE18957		
ID	AAE18957	standard; protein; 188 AA.
XX		
AC	AAE18957;	
XX		
DT	21-MAY-2002	(first entry)
XX		
DE	Human alpha-2b-interferon precursor protein.	
XX		
KW	Human; duckweed plant; alpha-2b-interferon; haemoglobin; vaccination;	
XX	collagen; 450 oxidase; industrial; chemical process; therapeutic; enzyme	
OS	Homo sapiens.	
XX		
FH	Key	Location/Qualifiers
FT	Peptide	1..23
FT	Protein	/label= Signal_peptide
FT		24..188
FT		/label= Mature_alpha_2b_interferon
XX		
PN	WO200210414-A2.	
XX		
PD	07-FEB-2002.	
XX		
PF	26-JUL-2001; 2001WO-US023400.	
XX		
PR	31-JUL-2000; 2000US-0221705P.	
PR	23-MAY-2001; 2001US-0293330P.	
XX		
PA	(BIOL-) BIOLEX INC.	
XX		
PI	Stomp A, Dickey L, Gasdaska J;	
XX		
DR	WPI; 2002-195966/25.	
XX		
PT	Producing recombinant polypeptides from duckweed plant culture, by	
PT	transforming culture with nucleotide sequence coding for the polypeptide	
PT	and signal peptide that directs polypeptide secretion into culture	
PT	medium.	
XX		
PS	Claim 21; Page 45-46; 47pp; English.	
XX		
CC	The invention relates to a method for producing a biologically active	
CC	recombinant polypeptide. The method comprises culturing a duckweed plant	
CC	culture or duckweed nodule culture, which is stably transformed to	
CC	express the polypeptide encoded by a nucleotide sequence that has been	
CC	modified for enhanced expression in duckweed and collecting the	
CC	polypeptide from duckweed plant or nodule culture. The method is useful	
CC	for producing a biologically active recombinant polypeptide and for the	

Query Match	100.0%;	Score 960;	DB 5;	Length 188;
Best Local Similarity	100.0%;	Pred. No. 3.8e-90;		
Matches 188;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0
QY 1 MALTFAALLVALVLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60				
Db 1 MALTFAALLVALVLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60				
QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIENLFSSTKSSAAWDETLDKFTYELLYQQLNDLLEA 120				
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIENLFSSTKSSAAWDETLDKFTYELLYQQLNDLLEA 120				
QY 121 CVIQGVGVETETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVAEIMRSFSLSTNL 180				
Db 121 CVIQGVGVETETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVAEIMRSFSLSTNL 180				
QY 181 QESLSRSKE 188				
Db 181 QESLSRSKE 188				
RESULT 5				
ABB07434				
ID ABB07434 standard; peptide; 188 AA.				
XX AC ABB07434;				
XX DT 09-APR-2002 (first entry)				
XX DE Interferon-alpha2 protein fragment.				
XX KW Interferon-beta-2; IFN-beta2; neuroprotective; cyostatic; virucide;				
XX KW antiarthritic; anti rheumatic; gene therapy; interferon-alpha2.				
XX OS Unidentified.				
XX PN WO200195929-A2.				
XX PD 20-DEC-2001.				
XX PF 18-JUN-2001; 2001WO-US041022.				
XX PR 16-JUN-2000; 2000US-0212046P.				
XX PR 15-JUN-2001; 2001US-00881050.				
XX PA (SCHD) SCHERING AG.				
XX PI Croze EM, Faulds D, Wagner TC;				
XX DR WPI; 2002-130714/17.				
XX PT Composition for treating multiple sclerosis, cancer and viral diseases				
XX PT and infections, comprises human interferon-beta-2 or its biologically-				
XX PT active fragment or derivative.				
XX DS Disclosure; Fig 4; 61pp; English.				
XX CC The invention relates to a pharmaceutical composition comprising a				

CC therapeutically effective amount of human interferon-beta-2 (IFN-beta2)
CC polypeptide. The composition is useful for treating multiple sclerosis in
CC mammals, in particular a human in need of such treatment, and also cancer
CC e.g. intraepithelial neoplasia and cervical cancer, autoimmune diseases
CC e.g. rheumatoid arthritis and viral diseases or infections. The
CC composition is useful for anti-oncogene regulation, antitumour activity,
CC antiviral activity, cell growth inhibition or anti-growth activity, anti-
CC proliferation, enhancement of cytotoxicity of lymphocytes, inducement or
CC inhibition of differentiation of target cells, immunoregulatory activity,
CC macrophage activation and down-regulation of oncogenes. Sequences
CC ABB07427-441 represent various interferon (IFN) sequences used for
CC alignment studies with the human IFN-beta2 polypeptide

XX Sequence 188 AA;

Query Match 100.0%; Score 960; DB 5; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 6
ABR55840
ID ABR55840 standard; protein; 188 AA.

AC ABR55840;
XX 02-SEP-2003 (first entry)
DT Human interferon-alpha (IFN-alpha).
DE Peptide remodeling; glycoconjugation; glycosyltransferase; glycan;
KW interferon-alpha; IFN-alpha; human.
XX Homo sapiens.

PN WO2003031464-A2.

PD 17-APR-2003.

PF 09-OCT-2002; 2002WO-US032263.

PR 10-OCT-2001; 2001US-0328523P.
PR 19-OCT-2001; 2001US-0344692P.
PR 28-NOV-2001; 2001US-0334233P.
PR 28-NOV-2001; 2001US-0334301P.
PR 07-JUN-2002; 2002US-0387292P.
PR 25-JUN-2002; 2002US-0391777P.
PR 17-JUL-2002; 2002US-0396594P.
PR 16-AUG-2002; 2002US-0404249P.
PR 28-AUG-2002; 2002US-0407527P.

PA (NEOS-) NEOSE TECHNOLOGIES INC.

PI De Frees S, Zopf D, Bayer R, Bowe C, Hakes D, Chen X;

XX WPI, 2003-449162/42.

DR N-PSDB; ACC78870.

XX Remodeling a peptide, by removing a saccharyl subunit from the peptide to
PT form truncated glycan, and adding or deleting glycosyl groups to a
PT peptide and/or adding modifying group of a peptide to remodel the
PT peptide.

PS Example; Fig 53B; 900pp; English.

XX The invention relates to a cell-free, in vitro method of remodeling a
XX peptide. The method involves removing a saccharyl subunit from the
CC peptide, thus forming a truncated glycan, and contacting the truncated
CC peptide with at least one glycosyltransferase and at least one glycosyl
CC glycan with at least one glycosyltransferase and at least one glycosyl
CC donor under conditions suitable to transfer at least one glycosyl donor
CC to the truncated glycan, thus remodeling the peptide. Conjugates can be
CC formed between a granulocyte colony stimulating factor (G-CSF) peptide,
CC interferon alpha peptide, interferon beta peptide, Factor VIIa peptide,
CC Factor IX peptide, follicle stimulating hormone peptide, erythropoietin
CC (EPO) peptide, granulocyte macrophage colony stimulating factor (GM-CSF)
CC peptide, interferon-gamma peptide, alpha-1-protease inhibitor (A-1-Pi)
CC peptide, beta-glucosidase peptide, tissue plasminogen activator (TPA)
CC peptide, interleukin-2 (IL-2) peptide, Factor VIII peptide, TNFalpha
CC receptor/immunoglobulin (Ig) G fusion peptide, urokinase peptide, anti-
CC glycoprotein IIb/IIIa monoclonal antibody peptide, chimeric anti HER2
CC antibody peptide, anti-respiratory syncytial virus (RSV) F peptide, anti-
CC CD20 antibody peptide, recombinant DNase peptide, anti-TNF alpha peptide,
CC insulin peptide, hepatitis B surface antigen (HbsAg), human growth
CC hormone (HGH) peptide, and a modifying group, where the modifying group
CC is covalently attached to the peptide through an intact glycosyl linking
CC group. The method is useful for a cell-free, in vitro method of
CC remodeling the above mentioned peptides. The present sequence represents
CC a human interferon-alpha (IFN-alpha)

XX Sequence 188 AA;

Query Match 100.0%; Score 960; DB 6; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFALLVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 7
AAO16454
ID AAO16454 standard; protein; 188 AA.

AC AAO16454;
XX 17-APR-2003 (first entry)
DT Human interferon alpha 2.

DE Human interferon alpha 2;
XX Human, cellular proliferation inhibitor; interferon alpha 2;
KW single nucleotide polymorphism; SNP; cancer; tumour; metabolic disease;
KW cardiovascular disease; infectious disease; immunological disease; HIV;
KW central nervous system disease; wound healing; chemotherapy side effect;
KW anaemia; osteoporosis; gastrointestinal disease; venereal disease; AIDS;
KW obesity; hepatitis; infectious pneumonia; Alzheimer's disease; allergy;
KW Parkinson's disease; multiple sclerosis; schizophrenia; depression;
KW graft versus host disease; asthma; psoriasis; rheumatoid arthritis;

KW Crohn's disease; ulcerative colitis; genital wart.
XX
OS Homo sapiens.
XX EPI236800-A2.
PN
XX 04-SEP-2002.
PD
XX 01-MAR-2002; 2002EP-00290515.
PF
XX 01-MAR-2001; 2001FR-00002843.
PR
XX (GENO-) GENODYSSEE.
PA
XX Escary J;
PI
XX WPI; 2003-185789/19.
DR N-PSDB; AAL51608.
XX
XX
PT An isolated polynucleotide encoding interferon alpha 2 containing single
PT nucleotide polymorphisms is useful in treating disease.
XX
XX
PS Claim 16; Page 33; 42pp; English.
XX
XX The invention comprises the amino acid and coding sequence of the human
CC interferon alpha 2 protein. The invention further relates to the
CC identification of single nucleotide polymorphisms (SNPs) within the human
CC interferon alpha 2 gene. The DNA and protein sequences of the invention
CC are useful for the treatment of: cancer; tumours; cardiovascular diseases
CC ; metabolic diseases; infectious diseases; central nervous system
CC diseases; immunological diseases; wound healing; chemotherapy side
CC effects; anaemia; osteoporosis; gastrointestinal diseases; venereal
CC diseases; obesity; hepatitis; HIV/AIDS; infectious pneumonias;
CC Alzheimer's disease; Parkinson's disease; multiple sclerosis;
CC schizophrenia; depression; graft versus host disease; allergies; asthma;
CC psoriasis; rheumatoid arthritis; Crohn's disease; ulcerative colitis; and
CC genital warts. The present amino acid sequence represents the human
CC interferon alpha 2 protein of the invention
XX
SQ Sequence 188 AA;

Query Match 100.0%; Score 960; DB 6; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPOEEFGNQFOKAETIPVLHEMIQIIFNLFTSKDSSAAMDETLDDKFYTELYQOLNDLEA 120
Db 61 FPOEEFGNQFOKAETIPVLHEMIQIIFNLFTSKDSSAAMDETLDDKFYTELYQOLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188
Db 181 QESLRSKE 188

RESULT 8
ADF77247
ID ADF77247 standard; protein; 188 AA.
XX
AC ADF77247;
XX
DT 26-FEB-2004 (first entry)
XX
DB Interferon alpha.
XX
KW Interferon alpha expression plasmid; tumour; IL-12.

XX Unidentified.
OS
XX
PN US2003181405-A1.
XX
XX 25-SEP-2003.
PD
XX 29-APR-2002; 2002US-00136837.
PF
XX 12-MAR-1999; 99US-00268135.
PR
XX (NORD/) NORDSTROM J L.
PA (PERI/) PERICLE F.
PA (ROL/) ROLLAND A.
PA (RALS/) RALSTON R O.
XX
PI Nordstrom JL, Pericle F, Rolland A, Ralston RO;
XX WPI; 2004-020834/02.
DR
XX
XX A mammalian interferon alpha expression plasmid is useful in gene therapy
PT to deliver interferon alpha to cells to modulate tumor activity in the
PT treatment of cancer.
XX
XX Disclosure; SEQ ID NO 9; 65pp; English.
PS
XX
XX The invention relates to a mammalian interferon alpha expression plasmid,
CC comprising a promoter and a synthetic 5' intron transcriptionally linked
CC with an interferon alpha coding sequence and a 3' untranslated region.
CC The mammalian interferon alpha expression plasmid is useful for treating
CC tumour growth. The present sequence is used in the exemplification of the
CC present invention.
XX
SQ Sequence 188 AA;

Query Match 100.0%; Score 960; DB 8; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALVALVLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPOEEFGNQFOKAETIPVLHEMIQIIFNLFTSKDSSAAMDETLDDKFYTELYQOLNDLEA 120
Db 61 FPOEEFGNQFOKAETIPVLHEMIQIIFNLFTSKDSSAAMDETLDDKFYTELYQOLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188
Db 181 QESLRSKE 188

RESULT 9
ADL24486
ID ADL24486 standard; protein; 188 AA.
XX
AC ADL24486;
XX
DT 03-JUN-2004 (first entry)
XX
DE Human interferon alpha protein.
XX
KW human; interferon alpha isoform; glycosylation; antiinflammatory;
KW hepatotropic; virucide; neuroprotective; cytostatic; IFN alpha.
XX
OS Homo sapiens.
XX
FH Key
FT Region Location/Qualifiers
31..44

```
FT      /note= "helix"
FT      Region      74..90
FT      /note= "helix"
FT      Region      139..156
FT      /note= "helix"
FT      Region      160..180
FT      /note= "helix"
XX
XX      WO2004019856-A2.
XX
XX      11-MAR-2004.
XX
XX      29-AUG-2003; 2003WO-KR001765.
XX
XX      31-AUG-2002; 2002KR-00052365.
XX
XX      (CJCJ-) CJ CORP.
XX
XX      Lee E, Park H, Kim H, Park J, Kim Y, Lee H, Koh H, Oh M,
XX      PI
XX      WPI; 2004-239105/22.
XX      DR
XX      N-PSDB; ADL24485.
XX
XX      New amino acid-modified human interferon alpha isoform having a sequence
XX      PT      formed at a specific amino acid residue position where glycosylation is
XX      PT      to take place, useful for treating e.g. chronic active hepatitis B.
XX
XX      Example 2; Fig 1; 52pp; English.
XX
XX      The present invention relates to a modified version of a human interferon
XX      CC      alpha (IFN alpha) isoform having a sequence formed at a specific amino
XX      CC      acid residue position so that glycosylation takes place at these sites.
XX      CC      Interferon may be used for the treatment of chronic active hepatitis B,
XX      CC      acute viral encephalitis, nasopharyngeal carcinoma, and the like. The
XX      CC      present sequence is the human interferon alpha protein.
XX
XX      Sequence 188 AA;
SQ
Query Match      100.0%; Score 960; DB 8; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
DB      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY      61 FPQEEFGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELYYOQLNDLEA 120
DB      61 FPQEEFGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELYYOQLNDLEA 120
QY      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
DB      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
QY      181 QESLSRSKE 188
DB      181 QESLSRSKE 188
RESULT 10
ADN49676
ID      ADN49676 standard; protein; 188 AA.
XX
XX      ADN49676;
XX
XX      15-JUL-2004 (first entry)
XX
XX      Human interferon alpha IFN-alpha protein SeqID 4.
XX
XX      human; erythropoietin; EPO; glycoconjugation; glycopeglylated EPO peptide;
XX      KW      anaemia; antianaemic; haematocrit level; kidney dialysis; haematology;
XX      KW      interferon alpha; IFN-alpha.
XX
```

```
OS      Homo sapiens.
XX
XX      WO2004033651-A2.
XX
XX      22-APR-2004.
XX
XX      08-OCT-2003; 2003WO-US031974.
XX
XX      09-OCT-2002; 2002WO-US032263.
XX      PR
XX      05-NOV-2002; 2002US-00287994.
XX      PR
XX      06-JAN-2003; 2003US-00360770.
XX      PR
XX      19-FEB-2003; 2003US-00360779.
XX      PR
XX      09-APR-2003; 2003US-00410945.
XX
XX      (NEOS-) NEOFSE TECHNOLOGIES INC.
XX
XX      De Frees S, Zopf D, Bayer R, Bowe C, Hakes D, Chen X;
XX      PI
XX      WPI; 2004-399848/37.
XX      DR
XX      N-PSDB; ADN49675.
XX
XX      Novel erythropoietin peptide comprising one or more glycans, having
XX      PT      glycoconjugate molecule covalently attached to peptide, useful for
XX      PT      treating anemia in mammal such as human.
XX
XX      PS      Disclosure; SEQ ID NO 4; 1018pp; English.
XX
XX      This invention relates to novel erythropoietin (EPO) peptides and the
XX      CC      remodelling and glycoconjugation of these naturally occurring peptides
XX      CC      thereof. Specifically, each EPO peptide comprises one or more glycans and
XX      CC      has a glycoconjugate molecule such as polyethylene glycol (PEG) attached
XX      CC      to it. Accordingly, the present invention provides glycopeglylated EPO
XX      CC      peptides that have either monoantennary, biantennary or triantennary
XX      CC      glycans covalently attached thereto. As such, these peptides are useful
XX      CC      for the treatment of anaemia, and hence exhibit antianaemic activities
XX      CC      working to increase haematocrit levels in mammals, in particular in
XX      CC      humans i.e. increasing the relative volume of blood occupied by
XX      CC      erythrocytes. Furthermore, EPO therapy can be used to treat kidney
XX      CC      dialysis patients. This polypeptide is a human protein sequence related
XX      CC      to the field of haematology, given in an exemplification of the
XX      CC      invention.
XX
XX      Sequence 188 AA;
SQ
Query Match      100.0%; Score 960; DB 8; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
DB      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY      61 FPQEEFGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELYYOQLNDLEA 120
DB      61 FPQEEFGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELYYOQLNDLEA 120
QY      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
DB      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
QY      181 QESLSRSKE 188
DB      181 QESLSRSKE 188
RESULT 11
ADU74352
ID      ADU74352 standard; protein; 188 AA.
XX
XX      ADU74352;
XX
XX      10-FEB-2005 (first entry)
XX
```

DE Human interferon-alpha.
XX
KW Hemostatic; Hepatotropic; Antianemic; Cytostatic; Osteopathic;
KW Antibacterial; Respiratory-Gen.; Antiinflammatory; Nephrotropic;
KW Antiinfectility; Antitubercular; Tuberculostatic; protein engineering;
KW bleeding; factor VIII deficiency; factor IX deficiency; liver cirrhosis;
KW infertility; anemia; end-stage renal disease; acute myelogenous leukemia;
KW osteoporosis; pulmonary fibrosis; tuberculosis.
XX
OS Homo sapiens.
XX
PN WO2004099231-A2.
XX
PD 18-NOV-2004.
XX
PF 09-APR-2004; 2004WO-US011494.
XX
PR 09-APR-2003; 2003US-00410897.
PR 09-APR-2003; 2003US-00410913.
PR 09-APR-2003; 2003US-00410930.
PR 09-APR-2003; 2003US-00410945.
PR 09-APR-2003; 2003US-00410962.
PR 09-APR-2003; 2003US-00410980.
PR 09-APR-2003; 2003US-00410997.
PR 09-APR-2003; 2003US-00411012.
PR 09-APR-2003; 2003US-00411026.
PR 09-APR-2003; 2003US-00411037.
PR 09-APR-2003; 2003US-00411043.
PR 09-APR-2003; 2003US-00411044.
PR 09-APR-2003; 2003US-00411049.
XX
PA (NEOS-) NEOSE TECHNOLOGIES INC.
XX
PI De Frees S, Zopf D, Bayer R, Bowe C, Hakes D, Chen X;
XX
DR WPI; 2004-833698/82.
DR N-PSDB; ADU74351.
XX
XX
PT Cell-free in vitro method of remodeling peptide comprising poly(ethylene
PT glycol) useful for generating glycopeptide suitable for therapeutic uses
PT in mammal, involves addition or deletion of glycosyl groups to peptide.
XX
PS Disclosure; SEQ ID NO 4; 1024pp; English.
XX
CC The invention relates to a cell-free in vitro method (M1) of remodeling a
CC peptide comprising poly(ethylene glycol). (M1) is useful for remodeling
CC protein to generate glycopeptide having desired glycosylation pattern
CC suitable for therapeutic use in mammal. (M1) is useful for remodeling
CC peptides chosen from immunoglobulin, erythropoietin, tissue-type
CC activator peptide, etc. (M1) is useful for remodeling (a) G-CSF which is
CC useful for treating acute myeloid leukemia (AML), non-myeloid cancer
CC patient receiving bone marrow transplant, (b) factor VII for treating
CC bleeding episode, factor VIII deficiency, factor IX deficiency, liver
CC cirrhosis, (c) FSH for patients undergoing intrauterine insemination, in
CC vitro fertilization and for infertile patient, (d) EPO for treating
CC anemia, anemic patients having chronic renal insufficiency and end stage
CC renal disease, anemic patient undergoing dialysis, (e) GM-CSF for
CC treating acute myelogenous leukemia, (f) IFN-gamma for treating malignant
CC osteoporosis, pulmonary fibrosis, tuberculosis, cryptococcal meningitis,
CC etc. The glycopeptide produced using (M1) has specific customized or
CC desired glycosylation pattern. (M1) allows efficient production of
CC improved therapeutic moiety. The present sequence represents the amino
CC acid sequence of a protein remodelled in the present invention
XX
XX Sequence 188 AA;
SQ
Query Match 100.0%; Score 960; DB 8; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 MALTFAALVALVLSCSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISLFCCLKDRHDFG 60
Db 1 MALTFAALVALVLSCSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISLFCCLKDRHDFG 60

Oy 61 PPOEEFGNQFOKAETIPVHEMIQQIFNLFSTKSSAAMDETLLDKPYTELQQQLNDLEA 120
Db 61 PPOEEFGNQFOKAETIPVHEMIQQIFNLFSTKSSAAMDETLLDKPYTELQQQLNDLEA 120
Oy 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAIMRSFSLSTNL 180
Oy 181 QESLSRKE 188
Db 181 QESLSRKE 188
RESULT 12
ADZ46960
ID ADZ46960 standard; protein; 188 AA.
XX
AC ADZ46960;
XX
DT 30-JUN-2005 (first entry)
XX
DE Human precursor alpha 2B interferon.
XX
KW Protein production; interferon; transgenic plant; codon usage.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..24 /note= "Signal peptide"
FT Protein 24..188 /note= "Mature interferon"
XX
XX WO2005035768-A1.
XX
PN 21-APR-2005.
XX
PD 16-APR-2004; 2004WO-US011968.
XX
PF 30-SEP-2003; 2003US-00675011.
XX
PR 05-MAR-2004; 2004US-00794615.
XX
XX (BIOL-) BIOLEX INC.
XX
PI Dickey L, Gasdaska J, Cox K, Peele CG, Spencer D;
XX
XX WPI; 2005-306370/31.
XX
DR
XX
XX Producing a recombinant polypeptide in a duckweed plant or nodule culture
PT comprises culturing within a duckweed culture medium a duckweed plant
PT culture or a duckweed nodule culture, which is stably transformed to
PT express the polypeptide.
XX
PS Disclosure; SEQ ID NO 4; 62pp; English.
XX
CC The invention relates to producing human growth hormone, an antibody or
CC alpha-interferon in a duckweed plant culture or a duckweed nodule culture
CC comprising culturing within a duckweed culture medium a duckweed plant
CC culture or a duckweed nodule culture, where the duckweed plant or nodule
CC culture is stably transformed to express the polypeptide, and collecting
CC the polypeptide from the culture. Also included are producing human
CC growth hormone (M1) in a duckweed plant culture or a duckweed nodule
CC culture (comprising culturing within a duckweed culture medium a duckweed
CC plant culture or a duckweed nodule culture, where the duckweed plant or
CC nodule culture is stably transformed to express the human growth hormone,
CC and where human growth hormone is expressed from a nucleotide sequence
CC comprising a coding sequence for a signal peptide that directs secretion of the
CC linked coding sequence for a signal peptide that directs secretion of the
CC human growth hormone into the culture medium and collecting the human
CC growth hormone from the duckweed culture medium), producing an antibody
CC (M2) in a duckweed plant culture or a duckweed nodule culture (comprising
CC the culturing and collecting steps in M1, and collecting the antibody

from the culture), producing human alpha-interferon (M3) in a duckweed plant culture or a duckweed nodule culture (comprising culturing within a duckweed culture medium a duckweed plant culture or a duckweed nodule culture, where the duckweed plant or nodule culture is stably transformed to express the human alpha;-interferon, and where the alpha-interferon is expressed from a nucleotide sequence comprising the leader sequence from the ribulose-bis-phosphate carboxylase small subunit 5B gene of *Lemna gibba* operably linked to a coding sequence for the human growth hormone, and an operably linked coding sequence for a signal peptide that directs secretion of the alpha-interferon into the culture medium; and collecting the alpha-interferon from the duckweed culture medium), the stably transformed duckweed plant culture or duckweed nodule culture (I), human growth hormone produced as in M1, an antibody produced according to M2, alpha-interferon produced according to M3 and enhancing the expression (M4) of a biologically active polypeptide in duckweed (comprising culturing a duckweed plant or nodule culture, where the duckweed plant or nodule culture is stably transformed to express the biologically active polypeptide and where the biologically active polypeptide is expressed from a nucleotide sequence comprising a coding sequence for the biologically active polypeptide and an operably linked nucleotide sequence comprising the leader from the ribulose-bis-phosphate carboxylase small subunit gene of *Lemna gibba*). The method is useful for producing human growth hormone in a duckweed plant culture or a duckweed nodule culture. The methods are also useful for producing an antibody and alpha-interferon in a duckweed plant culture. The method is useful for enhancing the expression of a biologically active polypeptide in duckweed. The present sequence represents human mature alpha 2B interferon.

SQ Sequence 188 AA;

Query Match	100.0%;	Score 960;	DB 9;	Length 188;
Best Local Similarity	100.0%;	Pred. No. 3.8e-90;		
Matches 188;	Conservative 0;	Mismatches 0;	Indels 0;	Gaps 0;

QY	1	MALTFALLVALLVLSCKSSCSVGCDBLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFG	60
Db	1	MALTFALLVALLVLSCKSSCSVGCDBLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFG	60
QY	61	FPQEEFGNOFOKAETI PVLHEMIQQIFNLSTKDDSSAAMDETL LDKFYTELYQOLNDLEA	120
Db	61	FPQEEFGNOFOKAETI PVLHEMIQQIFNLSTKDDSSAAMDETL LDKFYTELYQOLNDLEA	120
QY	121	CVIQGVGTETPLMKEDSILA VRKYPORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL	180
Db	121	CVIQGVGTETPLMKEDSILA VRKYPORITLLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL	180
QY	181	QESLRSKE	188
Db	181	QESLRSKE	188

RESULT 13

AED67247

ID AED67247 standard; protein; 188 AA.

AC AED67247;

DT 12-JAN-2006 (first entry)

DE Wild-type full length human interferon-alpha-2a polypeptide SEQ ID NO:23.

KW interferon-alpha; endocrine-gen.; osteopathic; ophthalmological;
 KW cytosstatic; vasotropic; therapeutic.

OS Homo sapiens.

PN US2005220762-A1

PD 06-OCT-2005.

PF 28-JAN-2005; 2005US-00046440.

XX

PR 02-FEB-2004; 2004US-0541528P.
PR 18-JUN-2004; 2004US-0580855P.
PR 18-JUN-2004; 2004US-0581175P.
PR 18-JUN-2004; 2004US-0581314P.
PR 22-DEC-2004; 2004US-0638616P.

PA (AMBR-) AMBRX INC.

PI Cho HS, Daniel TO, Hays A, Wilson TE;

DR WPI; 2005-777263/79.

DR N-PSDB; AED67250.

PT New human interferon polypeptide, useful for treating a disease, e.g.
PT gigantism, acromegaly, vascular eye disease, macular degeneration, or
PT sarcomas.

PS Example 11; SEQ ID NO 23; 129pp; English.

CC The invention relates to a novel human interferon (hIFN) polypeptide
CC comprising one or more non-naturally encoded amino acids. A hIFN
CC

ophthalmological, cytotractic, and vasototropic activity. The hIFN comprises a sequence of 165 amino acids (AED67248) encoded by a nucleic acid comprising a nucleotide sequence of 567 or 498 bp (AED67250 or AED67251).

CC The polypeptide, nucleic acid, composition, and method are useful for
CC treating a disease, e.g. gigantism, acromegaly, vascular eye disease,
CC macular degeneration, or sarcomas. The present sequence represents the
CC full length wild-type human interferon-alpha-2a polypeptide of the
CC invention.

50 Sequence 188 AA;

Query Match	100.0%;	Score 960;	DB 9;	Length 188;
Best Local Similarity	100.0%;	Pred. No. 3.8e-90;		
Matches 188; Conservative	0;	Mismatches	0;	Gaps 0;

[illegible]

RESULT 14

AE63137

ID AEE63137 standard; protein; 188 AA.

AC AEE63137;

DT 09-FEB-2006 (first entry)

DE Human interferon-alpha-2 amino acid sequence SEQ ID NO:8.

KM myocardial disease; cardiovascular-gen.; interferon-alpha.

OS Homo sapiens.

PN US2005276785-A1.

PD 15-DEC-2005.

PF 07-JUN-2005; 2005US-00147492.

Id

XX 09-JUN-2004; 2004US-0579024P.
PR (SCHD) SCHERING AG.
XX
XX
PI Groetzbach G, Kapp J, Kuehl U, Schultheiss H, Sowade O;
PI Stuerzebecher C;
XX
XX WPI; 2006-028347/03.
DR N-PSDB; AEF63136.
XX
XX Composition, useful to treat e.g. cardiomyopathy, endothelial
PT dysfunction, arrhythmia, dyspnea and palpitations, comprises an isolated
PT interferon beta/interferon alpha or interferon beta/interferon alpha
PT mutein.
XX
XX Disclosure; SEQ ID NO 8; 69pp; English.
PS
XX The invention relates to a composition (A) having interferon-beta (IFN-
CC beta) or interferon-alpha (INF-alpha) activity. (A) comprises a
CC therapeutically affective amount of an isolated IFN-beta, IFN-alpha, IFN-
CC beta mutein or IFN-alpha mutein for treatment of cardiomyopathy and
CC endothelial dysfunction, where the therapeutically effective amount is in
CC a range from about 30 to 500 mcg. (A) is useful in the treatment of
CC cardiomyopathy and endothelial dysfunction, such as chronic inflammatory
CC cardiomyopathy, chronic viral cardiomyopathy, valvular cardiomyopathy,
CC ischemic cardiomyopathy, and hypertensive cardiomyopathy. The present
CC sequence represents human interferon-alpha-2 (IFN-alpha-2), which is
CC given in the exemplification of the present invention.
XX
SQ Sequence 188 AA;

Query Match 100.0%; Score 960; DB 10; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MALTFAVLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
DB 1 MALTFAVLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
OY 61 FPOEEFGNQFOKAEITIPVLHEMIIQIIFNLFSTKSSAAMDETLLDKFYTELYQOINDLEA 120
DB 61 FPOEEFGNQFOKAEITIPVLHEMIIQIIFNLFSTKSSAAMDETLLDKFYTELYQOINDLEA 120
OY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
OY 181 QESLRSKE 188
DB 181 QESLRSKE 188

RESULT 15
AEF69475
ID AEF69475 standard; protein; 188 AA.
XX
AC AEF69475;
XX
DT 06-APR-2006 (first entry)
XX
DE Human interferon-alpha 2b.
XX
KW transgenic plant; interferon-alpha 2b; Antiinflammatory; Hepatotropic;
KW Virucide; cytostatic; Anti-HIV; Immunomodulator; hepatitis; cancer;
KW protein engineering; immune modulation.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1..23
FT /label= signal_peptide 24..188
FT Protein

PT /label= Mature_interferon-alpha_2b
XX US2006024272-A1.
XX 02-FEB-2006.
XX PD
XX 29-JUN-2005; 2005US-00172549.
XX PF
XX 29-JUL-2004; 2004US-0592479P.
XX PR
XX (LARG-) LARGE SCALE BIOLOGY CORP.
PA
PI Reinl SJ, Pogue GP;
XX
XX WPI; 2006-135331/14.
DR N-PSDB; AEF69474.
XX
XX Novel C-terminally truncated interferon polypeptide having enhanced
PT biological activity, useful for treating interferon affected disorder
PT such as viral hepatitis, hairy cell leukemia, Kaposi's sarcoma and immune
PT disorders.
XX
PS Example 1; SEQ ID NO 23; 54pp; English.

XX The present sequence of human interferon-alpha 2b, related to the novel
CC polypeptides of the current invention comprising human C-terminally
CC truncated interferon (IFN) having enhanced biological activity, is
CC encoded by a nucleotide insert AEF69474, cloned into the viral vector
CC DN15. Type I interferons exhibit a wide range of biological activity,
CC including antiviral, anti-proliferative, neoplastic and immunomodulatory
CC activities. Interferon-alpha is produced by human leukocytes. Plant-
CC produced IFN-alpha, fused to an extensin signal peptide and an
CC endoplasmic reticulum retention signal, demonstrates anti-viral and anti-
CC proliferative activities comparable to the bacterially produced protein
CC but contains C-terminal truncations that predominantly occur during the
CC processing of the plant material. The plant is Nicotiana benthamiana. To
CC assemble human interferon-alpha 2b for expression in tobacco mosaic virus
CC (TMV), an assembly reaction containing each of 16 oligonucleotides,
CC AEF69455, AEF69456, AEF69457, AEF69458, AEF69459, AEF69460, AEF69461,
CC AEF69462, AEF69463, AEF69464, AEF69465, AEF69466, AEF69467, AEF69468,
CC AEF69469, and AEF69470, were added to a PCR reaction. The amplification
CC product was re-amplified using the oligonucleotides AEF69455, and
CC AEF69470. IFN-alpha 2a was amplified under the same conditions except
CC that the oligonucleotide, AEF69457, was replaced by AEF69471. The
CC amplified sequences were blunt-cloned into TOPO TA cloning vector and
CC clones with the correct sequence were cloned into viral vector DN15.
CC Infectious transcripts were synthesized in vitro and used to inoculate 23
CC day post sow N. benthamiana plants. Systemically infected tissue was
CC harvested at 10 days post inoculation and protein extracted by either
CC homogenization or vacuum infiltration. C-terminally truncated interferon
CC is useful for treating an interferon affected disorder, which involves
CC administering the composition of the invention to a patient, where the
CC interferon affected disorders are viral hepatitis, cancer such as hairy
CC cell leukemia, Kaposi's sarcoma, chronic myelogenous leukemia and
CC metastatic malignant melanoma, and immune disorders. C-terminally
CC truncated interferon has enhanced biological activity such as anti-
CC proliferative activity and improved processing qualities such as
CC stability in crude extracts, yield and homogeneity at the C-terminus. C-
CC terminally truncated interferon can be purified easily, and has enhanced
CC anti-viral and immune modulatory activities.
XX
SQ Sequence 188 AA;

Query Match 100.0%; Score 960; DB 10; Length 188;
Best Local Similarity 100.0%; Pred. No. 3.8e-90;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1 MALTFAVLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
DB 1 MALTFAVLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
OY 61 FPOEEFGNQFOKAEITIPVLHEMIIQIIFNLFSTKSSAAMDETLLDKFYTELYQOINDLEA 120

Db	61	FPQEEFGNQKAEITIPVLHEMIQOIFNLESTKDSSAWDETLLDKFYTEL YQQLNDLEA	120
Qy	121	CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKCKYSPCAMEVVRAEIMRSFSLSTNL	180
Db	121	CVIQGVGTETPLMKEDSILAVRKYFORITLLYLKCKYSPCAMEVVRAEIMRSFSLSTNL	180
Qy	181	QESLRSKE	188
Db	181	QESLRSKE	188

Search completed: October 14, 2006, 07:56:45
Job time : 205 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioacceleration Ltd.

OM protein - protein search, using sw model

Run on: October 14, 2006, 07:57:02 ; Search time 41 Seconds
(without alignments)
441.189 Million cell updates/sec

Title: US-10-653-350-1

Perfect score: 960

Sequence: 1 MALTFALLVALVLVLSCKSSC.....EIMRSFSLSTNLSQESLRSKE 188

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283416 segs, 96216763 residues

Total number of hits satisfying chosen parameters: 283416

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : PIR 80:*

1: pirl:*
2: pirl2:*
3: pirl3:*
4: pirl4:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	957	99.7	188	1	IVHUA2 interferon alpha-2
2	851	88.6	165	2	I78570 alpha 2 interferon
3	809.5	84.3	189	1	IVHUA7 interferon alpha-5
4	808.5	84.2	189	1	IVHUI6 interferon alpha-1
5	793.5	82.7	189	1	IVHUI4 interferon alpha-1
6	781.5	81.4	189	2	I52347 interferon alpha-M
7	779.5	81.2	189	2	I51970 interferon precurs
8	772.5	80.5	189	1	IVHUA1 interferon alpha-1
9	770.5	80.3	189	1	IVHUA4B interferon alpha-1
10	768.5	80.1	189	2	I84464 interferon alpha-F
11	767.5	79.9	189	1	IVHUI6 interferon alpha-1
12	766.5	79.8	189	1	IVHUA5 interferon alpha-5
13	766.5	79.8	189	1	IVHUIF interferon alpha-1
14	760.5	79.2	189	1	IVHUA9 interferon alpha-1
15	756.5	78.8	189	2	I37584 IFN-alpha-N-protei
16	754.5	78.6	189	1	IVHUI8 interferon alpha-I
17	748.5	78.0	189	2	I53102 interferon-alpha-J
18	744.5	77.6	189	1	IVHUA0 interferon alpha-7
19	739.5	77.0	181	2	I56313 interferon alpha 2
20	732.5	76.3	189	1	IVHUA4 interferon alpha-4
21	728.5	75.9	176	2	I56314 interferon-alpha-
22	722.5	75.3	184	1	IVHOA4 interferon alpha-1
23	719.5	74.9	167	2	D25843 interferon alpha-G
24	718.5	74.8	184	1	IVHOA2 interferon alpha-I
25	710.5	74.0	184	1	IVHOA3 interferon alpha-I
26	704.5	73.4	184	1	IVHOA1 interferon alpha-I
27	690.5	71.9	167	2	E25843 interferon alpha-F
28	678.5	70.7	167	2	F25843 interferon alpha-J
29	665.5	69.3	162	2	C25843 interferon alpha-B

30	640.5	66.7	189	2	S23709 interferon alpha-1
31	603.5	62.9	189	1	IVMSA5 interferon alpha-I
32	596.5	62.1	189	1	IVBO11 interferon alpha-I
33	591.5	61.6	189	1	IVBO1D interferon alpha-I
34	590.5	61.5	189	1	IVBO1A interferon alpha-I
35	590.5	61.5	189	1	IVBO1B interferon alpha-I
36	588.5	61.3	189	1	IVMSA1 interferon alpha-I
37	581.5	60.6	189	1	IVBO1C interferon alpha-I
38	580.5	60.5	190	2	I49774 alpha-interferon -
39	579.5	60.4	190	2	A24401 interferon alpha-1
40	572.5	59.6	190	1	IVMSA2 interferon alpha-2
41	568.5	59.2	192	1	IVRTA1 interferon alpha-1
42	561.5	58.5	190	2	I49772 interferon alpha-7
43	561.5	58.5	190	2	I49775 interferon alpha-B
44	554.5	57.8	189	1	IVMSA6 interferon alpha-I
45	552.5	57.6	189	2	I49773 murine interferon

ALIGNMENTS

RESULT 1
IVHUA2
interferon alpha-2 precursor (allele a) [validated] - human
N:Alternate names: IFN-alpha2; interferon alpha-3; interferon alpha-A; leukocyte interf
C:Species: Homo sapiens (man)
C:Date: 31-Oct-1980 #sequence revision 01-Sep-1981 #text change 09-Jul-2004
C:Accession: A93234, D93249, A93888, I59458, A94252, A25843, A01828, C61478, S15848, B4
R:Goeddel, D.V.; Yelverton, E.; Ullrich, A.; Heyneker, H.L.; Miozzari, G.; Holmes, W.;
ss, M.; Familletti, P.C.; Pestka, S.
Nature 287, 411-416, 1980
A:Title: Human leukocyte interferon produced by Escherichia coli is biologically active.
A:Reference number: A93234, MUID:81052322, PMID:6159538
A:Accession: A93234
A:Molecule type: DNA
A:Residues: 1-188 <GOE>
A:Cross-references: UNIPROT:P01563, UNIPARC:UPI000012D643, GB:V00544, NID:g32730, PIDN:
A:Experimental source: clone pL31
R:Goeddel, D.V.; Leung, D.W.; Dull, T.J.; Gross, M.; Lawn, R.M.; McCandless, R.; Seeburg
Nature 290, 20-26, 1981
A:Title: The structure of eight distinct cloned human leukocyte interferon cDNAs.
A:Reference number: A93249, MUID:81148795, PMID:6163083
A:Accession: D93249
A:Molecule type: mRNA
A:Residues: 1-188 <GO2>
A:Cross-references: UNIPARC:UPI000012D643, GB:V00549, NID:g32744, PIDN:CAA23810.1; PID:
A:Note: eight classes of interferon alpha clones were identified; this sequence is deri
R:Lawn, R.M.; Gross, M.; Houck, C.M.; Franke, A.E.; Gray, P.V.; Goeddel, D.V.
Proc. Natl. Acad. Sci. U.S.A. 78, 5435-5439, 1981
A:Title: DNA sequence of a major human leukocyte interferon gene.
A:Reference number: A93888, MUID:82060261, PMID:6170983
A:Accession: A93888
A:Molecule type: DNA
A:Residues: 1-45, 'R', 47-188 <LAW>
A:Cross-references: UNIPARC:UPI0000034B3A, GB:J00207, NID:g184581, PIDN:AAB59402.1; PID:
A:Experimental source: clone lambda-alpha-2
R:Oliver, G.; Balbas, P.; Valle, F.; Soberon, X.; Bolivar, F.
Rev. Latinoam. Microbiol. 27, 141-150, 1985
A:Title: [Cloning of human leukocyte interferon cDNA and a strategy for its production ;
A:Reference number: I59458, MUID:86069501, PMID:3906813
A:Accession: I59458
A:Status: preliminary; translated from GB/EMBL/DBJ
A:Molecule type: mRNA
A:Residues: 1-188 <RES>
A:Cross-references: UNIPARC:UPI000012D643, GB:MS4886, NID:g186498, PIDN:AAA59181.1; PID:
R:Streuli, M.; Nagata, S.; Weissmann, C.
Science 209, 1343-1347, 1980
A:Title: At least three human type alpha interferons: structure of alpha2.
A:Reference number: A94252, MUID:81015442, PMID:6158094
A:Accession: A94252
A:Molecule type: mRNA
A:Residues: 7-45, 'R', 47-188 <STR>
A:Cross-references: UNIPARC:UPI000002C6D4, GB:V00548, NID:g32740, PIDN:CAA23809.1; PID:5

R.Chara, O.; Teraoka, H.
FEBS Lett. 211, 78-82, 1987
A;Title: Anomalous behavior of human leukocyte interferon subtypes on polyacrylamide gel
A;Reference number: A91374; MUID:87105954; PMID:3803589
A;Accession: A25843
A;Status: nucleic acid sequence not shown; not compared with conceptual translation
A;Molecule type: mRNA
A;Residues: 'M', 24-188 <OHA>
A;Cross-references: UNIPARC:UPI000002C5A3
A;Note: engineered sequence of mature form expressed in *Escherichia coli*
R.Allen, G.; Fantes, K.H.
Nature 287, 408-411, 1980
A;Title: A family of structural genes for human lymphoblastoid (leukocyte-type) interferon
A;Reference number: A01828; MUID:81052321; PMID:6159537
A;Accession: A01828
A;Molecule type: protein
A;Residues: 24-42, 'Z', 44-45, 'R', 47-74, 'A', 76, 'S', 78-98, 'X', 100-105, 'D', 107-109, 'P', 111-112
A;Cross-references: UNIPARC:UPI000017365A; UNIPARC:UPI000017365B
A;Note: residues at positions 83, 86, and 139 may be Ile or possibly Leu; those at position 100 are
A;Note: 57-Arg, 75-Thr, 77-Pro, and 96-Glx were also found
R.Fukuda, S.; Ando, S.; Sanou, O.; Tanai, M.; Fujii, M.; Masaki, N.; Nakamura, K.I.; Arima,
Lymphokine Res. 7, 175-185, 1988
A;Title: Simultaneous production of natural human tumor necrosis factor-alpha, -beta and
A;Reference number: A61478; MUID:88301617; PMID:2841543
A;Accession: C61478
A;Molecule type: protein
A;Residues: 24-45, 'R', 47-53 <FUK>
A;Cross-references: UNIPARC:UPI000017365C
A;Experimental source: B-cel lymphoblastoid cell line BALL-1
R.Adolf, G.R.; Kalsner, I.; Ahorn, H.; Maurer-Fogy, I.; Cantell, K.
Biochem. J. 276, 511-518, 1991
A;Title: Natural human interferon-alpha-2 is O-glycosylated.
A;Reference number: S15848; MUID:91264809; PMID:2049076
A;Accession: S15848
A;Molecule type: protein
A;Residues: 24-45, 'R', 47-53 <BIO>
A;Cross-references: UNIPARC:UPI000017365C
A;Experimental source: leukocytes
R.Zoon, K.C.; Miller, D.; Bekisz, J.; zur Nedden, D.; Enterline, J.C.; Nguyen, N.Y.; Hu,
J. Biol. Chem. 267, 15210-15216, 1992
A;Title: Purification and characterization of multiple components of human lymphoblastoid
A;Reference number: A42753; MUID:92340576; PMID:1634550
A;Accession: B42753
A;Molecule type: protein
A;Residues: 'X', 25-45, 'R', 47-51, 'X', 53-55, 'XX', 58-65 <ZOO>
A;Cross-references: UNIPARC:UPI000017365D
A;Experimental source: Sendai virus-induced Namalwa cells
R.Wetzel, R.
Nature 289, 606-607, 1981
A;Title: Assignment of the disulphide bonds of leukocyte interferon.
A;Reference number: A93244; MUID:81123083; PMID:6162107
A;Contents: annotation; disulfide bonds
R.Mugnolo, N.J.; Windsor, W.T.; Hruza, A.; Reichert, P.; Tsaropoulos, A.; Baldwin, S.;
Proteins 17, 62-74, 1993
A;Title: A homology model of human interferon alpha-2.
A;Reference number: A44748; MUID:94052087; PMID:8234245
A;Contents: annotation; theoretical model
R.Gewirtz, D.; Salom, C.; Barber, K.; Macbride, S.; Cooper, H.; Lewis, A.; Wood, J.; Crow,
J. Interferon Res. 13, 227-231, 1993
A;Title: Analysis of interferon-alpha 2 sequences in human genomic DNA.
A;Reference number: I56312; MUID:93375201; PMID:8366289
A;Accession: I56312
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA
A;Residues: 1-72 <REM>
A;Cross-references: UNIPARC:UPI00000701A9; GB:S64979; NID:9408874; PIDN:AAD13960.1; PID:
R.Zhao, X.X.; Li, B.L.; Langer, J.A.; Van Riper, G.; Pestka, S.
Anal. Biochem. 178, 342-347, 1989
A;Title: Construction and phosphorylation of a fusion protein Hu-IFN-alpha A/gamma.
A;Reference number: I36908; MUID:89321045; PMID:2502045
A;Accession: I36909
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: DNA

```
A;Residues: 'M',24-188 <RE2>
A;/Cross-references: UNIPARC:UPI000002C5A3, EMBL:X15631, NID:g22771, PIDN:CAA33638.1; PIR:
C;Genetics:
A/Gene: GDB:IFNA2
A;/Cross-references: GDB:136359; OMIM:147562
A;/Map position: 9p22-9p22
C;/Superfamily: interferon alpha
C;/Keywords: antiviral; cytokine; glycoprotein; leukocyte
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-188/Product: interferon alpha-2 #status experimental <MAT>
F;24-121,52-161/Disulfide bonds: #status experimental
F;129/Binding site: carbohydrate (Thr) (covalent) #status experimental

Query Match          99.7%; Score 957; DB 1; Length 188;
Best Local Similarity 99.5%; Pred. No. 3.5e-81;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      1 MALTFALLVALLVLSCKSSCSVGCGLPQTHSLGSRRITMLLAQMRRISLFSCLDKDRHDFG 60
       |||||
Db      1 MALTFALLVALLVLSCKSSCSVGCGLPQTHSLGSRRITMLLAQMRRISLFSCLDKDRHDFG 60

QY      61 FPOEEFGNGFOKAETIPVLHEMIQQIENLESTKDSAAWDETLDDKFYTELYQQINDLEA 120
       |||||
Db      61 FPOEEFGNGFOKAETIPVLHEMIQQIENLESTKDSAAWDETLDDKFYTELYQQINDLEA 120

QY      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRAEIMRSFSISTNL 180
       |||||
Db      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRAEIMRSFSISTNL 180

QY      181 QESLRKSKE 188
       |||||
Db      181 QESLRKSKE 188
```

```
RESULT 2
178570
alpha 2 interferon - human (fragment)
C;Species: Homo sapiens (man)
C;Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
C;Accession: I78570
R.Weber, H.; Weissmann, C.
Nucleic Acids Res. 11, 5661-5669, 1983
A>Title: Formation of genes coding for hybrid proteins by recombination between related
A;Reference number: I58213; MUID:83299241; PMID:6310510
A;Accession: I78570
A;Status: preliminary; translated from GB/EMBL/DDBJ .
A;Molecule type: DNA
A;Residues: 1-165 <RES>
A;Cross-references: UNIPROT:P01563; UNIPARC:UPI0000049830; GB:M29883; NID:g184585; PIDN
C;Genetics:
A;Gene: IFNA
C;Superfamily: interferon alpha

Query Match      88.6%; Score 851; DB 2; Length 165;
Best Local Similarity   100.0%; Pred. No. 1.9e-71;
Matches 165; Conservative    0; Mismatches     0; Indels       0; Gaps        0;

QY      24 CDLPOTHSLSGSRRTMLLAQMRRISLFSCLKDRHDFGFPOEEFGNQFOKAETIPLVHEMI 83
|||||
Db       1 CDLPQTSLSGSRRITMLLAQMRRI SLFSCDKRDHFGEFPQE EFGNQFOK AETTIVLVHEMI 60
|||||

QY      84 QQIFNLSTKDSSAAWDETLLD KFYTEL YQQINDLEACVI QGVGTET PLMKEDSI LAVR 143
|||||
|||
Db       61 QQIFNLSTKDSSAAWDETL LDKFYTE LYQQNDLEACVI QGVGTET P L MKEDSI LAV R 120
|||||

QY      144 KYFORITLYLK EKYS PCAW EVRAEIMRS FSLTNLOESLR SK E 188
|||||
|||
Db       121 KYFORITLYLK EKYS PC AW EVRAEI MR SF SLT NL O ES LR SK E 165


RESULT 3
IVHUAV
interferon alpha-5 precursor - human
```


A/Title: Formation of genes coding for hybrid proteins by recombination between related,
A/Reference number: I58213; MUID:63299241; PMID:6310510
A/Accession: I58213
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: DNA
A/Residues: 24-189 <RES>
A/Cross-references: UNIPARC:UPI000002F8DA; GB:M29884; NID:g184583; PIDN:AAA52714.1; PID:
R:Henco, K.; Brosius, J.; Fujisawa, A.; Fujisawa, J.I.; Haynes, J.R.; Hochstadt, J.; Kov
J. Mol. Biol. 185, 227-260, 1985
A/Title: Structural relationship of human interferon alpha genes and pseudogenes.
A/Reference number: A92916; MUID:86037205; PMID:4057246
A/Accession: S43715
A/Molecule type: DNA
A/Residues: 1-189 <HEN>
A/Cross-references: UNIPARC:UPI000002C6D3; EMBL:X75934.
R:Roberts, N.
submitted to the EMBL Data Library, December 1993
A/Reference number: S41196
A/Accession: S41196
A/Molecule type: DNA
A/Residues: 1-9, 'A', 11-189 <ROS>
A/Cross-references: UNIPARC:UPI000002C35C; EMBL:X75934; NID:g439666; PIDN:CAA53538.1; PT
C/Genetics:
A/Gene: GDB:IFNA1
A/Cross-references: GDB:136353; OMIM:147660
A:Map position: 9p22-9p22
C:Superfamily: interferon alpha
C:Keywords: antiviral; cytokine; leukocyte
F:1-23/Domain: signal sequence #status predicted <SIG>
F:24-189/Product: interferon alpha-1 #status predicted <MAT>
F:24-122, 52-162/Disulfide bonds: #status predicted

```

Query Match      80.5%; Score 772.5; DB 1; Length 189;
Best Local Similarity 82.0%; Pred. No. 4.1e-64;
Matches 155; Conservative 10; Mismatches 23; Indels 1; Gaps 1;

OY      1 MALTFAVLVALVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
      |||:::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||
DB      1 MASPFALMLVLVLSCKSSCSGLGCDLPETHSLDNRTMLLAQMSRISPSSTCLMDRHDFG 60

OY      61 PPOEEF-GNQFOKAEFTIPVLEHMIQOIFNLFTSKDSSAAWDETLDDKFTYELVQOLNDLE 119
      |||::|::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||
DB      61 PPOEEFDGNQFOKAPASVLEHLLIQOIFNLFTSKDSSAAWDETLDDKFTCTELVQOLNDLE 120

OY      120 ACVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTN 179
      |||::|::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||::|:|||||
DB      121 ACVMQEEERVGETPLMADNSILAVKYPFRITLYLTEKKYSPCAMEVVRRAEIMRSLSLSTN 180

OY      180 LQESLRKE 188
      |||::|::|:|||||
DB      181 LQERLRKE 189

RESULT 9
IVHU4B
interferon alpha-I-4b precursor - human
N:Alternate names: HuIFN-alpha-I-4b; type I interferon
C:Species: Homo sapiens (man)
C:Date: 28-Dec-1987 #sequence_revision 28-Dec-1987 #text_change 09-Jul-2004
C:Accession: E23753
R:Henco, K.; Brosius, J.; Fujisawa, A.; Fujisawa, J.I.; Haynes, J.R.; Hochstadt, J.; Kov
J. Mol. Biol. 185, 227-260, 1985
A:Title: Structural relationship of human interferon alpha genes and pseudogenes.
A:Reference number: A92916; MUID:86037205; PMID:4057246
A:Accession: E23753
A:Molecule type: DNA
A:Residues: 1-189 <HEN>
A:Cross-references: UNIPROT:P05014; UNIPARC:UPI0000047761; GB:X02955; NID:g32656; PIDN:C
C:Genetics:
A:Gene: GDB:IFN1@
A:Cross-references: GDB:119328; OMIM:147660
A:Map position: 9p22-9p22
C:Superfamily: interferon alpha

```

C:Keywords: antiviral
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-189/Product: interferon alpha-1-4b #status predicted <MAT>
F;24-122,52-162/Disulfide bonds: #status predicted

Query Match	80.3%;	Score 770.5;	DB 1;	Length 189;
Best Local Similarity	80.4%;	Pred. No. 6.3e-64;		
Matches 152;	Conservative 17;	Mismatches 19;	Indels 1;	Gaps 1;

```
QY      1 MALTFAVLVALVLSCKSSCSVGCDLPÖTHSLGSRRTLMLLAQMRISLFSCLKDRHDFG   60  
        |||:::||||| | :|::||| ||| ::||| ||| ||| ||| |||  
Db      1 MALSFSLMAVLVLSYKSI CSLGCDLPÖTHSLGNRRALILLAQMGRISHFSCCLKDRHDFG   60  
  
QY      61 FPÖEEF-GNÖFOKAETIPVLHEMIÖOI FNLFSTKDSSAAWDETLDKFYTELYÖQLNDLE  119  
        ||::|||::||| : | ||||||| ||| |||::|||::||| ||| ||| |||  
Db      61 FPEEFDGHQFOKTQAISVLHEMIÖQTENLFSTEDSSAABEQSLEKEFTSELYÖQLNDLE  120  
  
QY      120 ACVIQGVTETPLMKEDSILA VRKYFORITLYLKEKKYS PCAWEVRAEIMRSFSLSSTN  179  
         ||||| ||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||  
Db      121 ACVIQEVGVEETPLMNVD S ILAVRKYFORITLYLTEKKYSPCAWEVRAEIMRSLSFSTN  180  
  
QY      180 LQESLR SK E    188  
        ||: || |:   
Db      181 LÖKR LR KD  189
```

RESULT 10
I84464

interferon-alpha-F - human
C/Species: Homo sapiens (man)
C/Date: 02-Aug-1996 #sequence_revision 02-Aug-1996 #text_change 09-Jul-2004
C/Accession: I84464; I37583
R/Gren, E.Y.; Berzin, V.M.; Tsimanis, A.Y.; Apsalon, U.R.; Vishnevskii, Y.I.; Yansone, I.
.A.; Lozha, V.P.; Kavsan, V.M.; Efimov, V.A.; Sverdlov, E.D.
Dokl. Biochem. 269, 91-95, 1983
A/Title: A new type of leukocytic interferon.
A/Reference number: I37583
A/Accession: I84464
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-189 <RES>
A/Cross-references: UNIPROT:P01568; UNIPARC:UPI000002C35A; GB:M12350; NID:g184598; PIDN:
A/Accession: I37583
A/Status: preliminary; translated from GB/EMBL/DBJ
A/Molecule type: mRNA
A/Residues: 1-189 <RES>
A/Cross-references: UNIPARC:UPI000002C35A; EMBL:X00145; NID:g32724; PIDN:CAA24980.1; PIR
C/Genetics:
A/Gene: IFNA
C/Superfamily: interferon alpha

Query Match	80.1%;	Score 768.5;	DB 2;	Length 189;
Best Local Similarity	81.5%;	Pred. No. 9.6e-64;		
Matches 154;	Conservative 13;	Mismatches 21;	Indels 1;	Gaps 1;

QY	1	MALTFALLVALVLSCSSCSVGCDDLPOTHSLGSRRTIMLLAQMRISLSFCLKDRHDFG	60
Db	1	MALSFSLMAVLVLSYKSISCSLGCDDLPOTHSLGNRRALILLAQMGRIISPFSCLKDRHDFG	60
QY	61	FPOEEF-GNÖFOKAEITPVLHEMIOQIFNLFSTKDOSSAAWDETLDKFTELYQQLNDLE	119
Db	61	FPOEEFDGNÖFOKQAISVLHEMIOQTENLFSTKDOSSATWEGSLTEKFESTELNQQLNDLE	120
QY	120	ACVIOGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVYRAEIMRSFSLSTN	179
Db	121	ACVIOGVGVEETPLMNVDSILAVKKYFORITLYLTEKKYSPCAMEVYRAEIMRSFSLSKI	180
QY	180	LOESLSRKE	188
Db	181	FÖERLRRKE	189

RESULT 11


```

IVHU16
interferon alpha-I-16 precursor - human
N;Alternate names: HU1F6N-alpha-I-16; interferon alpha-I-WA; type I interferon
C;Species: Homo sapiens (man)
C;Date: 28-Dec-1987 #sequence revision 28-Dec-1987 #text_change 09-Jul-2004
C;Accession: G23753; A22068; I73334
R;Henco, K.; Brosius, J.; Fujisawa, A.; Fujisawa, J.I.; Haynes, J.R.; Hochstadt, J.; Kov
J. Mol. Biol. 185, 227-260, 1985
A;Title: Structural relationship of human interferon alpha genes and pseudogenes.
A;Reference number: A92916; MUID:86037205; PMID:4057246
A;Accession: G23753
A;Molecule type: DNA
A;Residues: 1-189 <HEN>
A;Cross-references: UNIPROT:P05015; UNIPARC:UPI0000047763; GB:X02957; NID:g32653; PIDN:C
R;Torczynski, R.M.; Fuke, M.; Bollon, A.P.
Proc. Natl. Acad. Sci. U.S.A. 81, 6451-6455, 1984
A;Title: Human genomic library screened with 17-base oligonucleotide probes yields a nov
A;Reference number: A22068; MUID:85038533; PMID:6387705
A;Accession: A22068
A;Molecule type: DNA
A;Residues: 1-189 <TOR>
A;Cross-references: UNIPARC:UPI0000047763; GB:X02055; NID:g184620; PIDN:AAA52727.1; PID:
J;Gren, E.; Berzin, V.M.; Jansone, I.; Tsimanis, A.; Vishnevsky, Y.; Apsalons, U.
J. Interferon Res. 4, 609-617, 1984
A;Title: Novel human leukocyte interferon subtype and structural comparison of alpha int
A;Reference number: I56313; MUID:85056523; PMID:6548765
A;Accession: I73334
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-189 <RES>
A;Cross-references: UNIPARC:UPI0000047763; GB:M28585; NID:g184643; PIDN:AAA36042.1; PID:
C;Genetics:
A;Gene: GDB:IFNA16
A;Cross-references: GDB:136357; OMIM:147580
A;Map position: 9p22-9p22
A;Introns: #status absent
C;Superfamily: interferon alpha
C;Keywords: antiviral; cytokine; leukocyte
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-189/Product: interferon alpha-I-16 #status predicted <MAT>
F;24-122,52-162/Disulfide bonds: #status predicted

Query Match          79.9%; Score 767.5; DB 1; Length 189;
Best Local Similarity 81.0%; Pred. No. 1.2e-63;
Matches 153; Conservative 12; Mismatches 23; Indels 1; Gaps 1;

QY      1 MALTFAIVAVLVLSCKSSCSVGCGLPQTHSLGSRRTLMLLAQMRRISLFSCDKRDHDEG 60
      |||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      1 MALSFSLMAVVLVLSYKSIKSLGCDLPQTHSLGNRRALILLAQMGRISHFSCDKRDYDEG 60

QY      61 FPQEEF-GNQFQKAETIPVLHEMIOQIFNLFSTKDDSSAAWDETLDDKFYTELYQOINDLE 119
      |||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      61 FPQEVFDGNQFQKAQAIISAFHEMIOQTFNLFSTKDDSSAAWDETLDDKFYTELFQOINDLE 120

QY      120 ACVIGGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIWRSSFLSTN 179
      |||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      121 ACVTQEVGVEIATLMNEDSILAVRKYFORITLYLMGKKYSPCAMEVVRAEIWRSSFSSTN 180

QY      180 LQESLRSKE 188
      ||:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|:|
Db      181 LQKGLRRKD 189

RESULT 12
IVHUAS
interferon alpha-5 precursor - human
C;Species: Homo sapiens (man)
C;Date: 01-Sep-1981 #sequence_revision 01-Sep-1981 #text_change 09-Jul-2004
C;Accession: A60937; A01830
R;Bartholomew, C.; Windass, J.D.
J. Interferon Res. 9, 407-417, 1989
A;Title: Identification of a functional allele of a human interferon-alpha gene previous
A;Reference number: A60937; MUID:89328015; PMID:2526839

```

```

A/Accession: A60937
A/Molecule type: DNA
A/Residues: 1-189 <BAR>
A/Cross-references: UNIPROT:P01566; UNIPARC:UPI0000047765
A/Note: this genomic sequence, SMTIIL1A, encodes a functional allele for alpha interference and is a pseudogene
R/Goeidel, D.V.; Leung, D.W.; Dull, T.J.; Gross, M.; Lawn, R.M.; McCandliss, R.; Seeburg, Nature 290, 20-26, 1981
A/Title: The structure of eight distinct cloned human leukocyte interferon cDNAs.
A/Reference number: A93249; MUID:81148795; PMID:6163083
A/Accession: A01830
A/Molecule type: mRNA
A/Residues: 1-189 <GOE>
A/Cross-references: UNIPARC:UPI0000047765; GB:V00551; GB:J00209; NID:g32748; PIDN:CAA233
A/Note: eight classes of interferon alpha clones were identified; this sequence is derived from C/Genetics:
A/Gene: GDB:IFN1@
A/Cross-references: GDB:119328; OMIM:147660
A/Map position: 9p22-9p22
C/Superfamily: interferon alpha
C/Keywords: antiviral
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-189/Product: interferon alpha-I-F #status predicted <MAT>
F;24-122,52-162/Disulfide bonds: #status predicted

Query Match          79.8%; Score 766.5; DB 1; Length 189;
Best Local Similarity 80.4%; Pred. No. 1.5e-63;
Matches 152; Conservative 16; Mismatches 20; Indels 1; Gaps 1;

QY      1 MALTFALLVALLVLSCKSSCSVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
        |||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db       1 MALSFLLMAVLVLVSYSKISCLSGCDLPQTHSLGNRRALILLGMGRISPSCDKRHDFR 60

QY      61 PPOEEF-GNQFOKAETIPVLHEMIQQFLNLFTSKDSSAAWDETLLDKFYTELQQQLNDLE 119
        |||||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db       61 IPOEEFDGNQFOKAQAIVLHEMIQQTLNFLSTEDSSAAWEQSILEKSTELYYOQLNDLE 120

QY      120 ACVIQGVTGTPTPLMKEDSILAVRKYPORITLYLKPKKYSPCAMEVVRAEIMRSFSLSTN 179
        |||||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||::|||
Db       121 ACVIQEVGVETPTPLMNEDSILAVRKYPORITLYLERKYSPCAMEVVRAEIMRSLSFSTN 180

QY      180 LQESLRKE 188
        ||::|||:
Db       181 LQRLRRKD 189

RESULT 13
IVHUUF
interferon alpha-I-F precursor - human
N/Alternate names: HuIFN-alpha-I-F; Leif F; type I interferon
C/Species: Homo sapiens (man)
C/Date: 01-Sep-1981 #sequence_revision 01-Sep-1981 #text_change 09-Jul-2004
C/Accession: A01832
R/Goeidel, D.V.; Leung, D.W.; Dull, T.J.; Gross, M.; Lawn, R.M.; McCandliss, R.; Seeburg, Nature 290, 20-26, 1981
A/Title: The structure of eight distinct cloned human leukocyte interferon cDNAs.
A/Reference number: A93249; MUID:81148795; PMID:6163083
A/Accession: A01832
A/Molecule type: mRNA
A/Residues: 1-189 <GOE>
A/Cross-references: UNIPROT:P01568; UNIPARC:UPI0000047762; GB:V00540; GB:J00212; NID:g32748
A/Note: eight classes of interferon alpha clones were identified; this sequence is derived from C/Genetics:
A/Gene: GDB:IFN1@
A/Cross-references: GDB:119328; OMIM:147660
A/Map position: 9p22-9p22
C/Superfamily: interferon alpha
C/Keywords: antiviral
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-189/Product: interferon alpha-I-F #status predicted <MAT>
F;24-122,52-162/Disulfide bonds: #status predicted

```


Best Local Similarity 81.0%; Pred. No. 1.5e-63;
Matches 153; Conservative 14; Mismatches 21; Indels 1; Gaps 1;
QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTLMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALSFSLLMAVLLVLSYKSICSLGCDLPQTHSLGNRRALITLLAQMGRISPSFCLKDRHDFG 60
QY 61 FPQEEF-GNQFQKAETIPVLHEMIOQIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLE 119
Db 61 FPQEEFDGNQFQKAISVLHEMIOQTENLSTKSSATWEGSLLEKFESTELNQQLNDME 120
QY 120 ACVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAWEVVRRAEIMRSFSLSTN 179
Db 121 ACVIQEVGEETPLMNVDSILAVKKYFORITLLYLTEKKYSPCAWEVVRRAEIMRSFSLSKI 180
QY 180 LQESLRSKE 188
Db 181 FQERLRKE 189

RESULT 14
IVHUA9
interferon alpha-17 precursor - human
N;Alternate names: interferon alpha-9; interferon alpha-1'
C;Species: Homo sapiens (man)
C;Date: 01-Sep-1981 #sequence revision 01-Sep-1981 #text_change 09-Jul-2004
C;Accession: A01835; A22255; C42753
R;Lawn, R.M.; Adelman, J.; Dull, T.J.; Gross, M.; Goeddel, D.; Ullrich, A.
Science 212, 1159-1162, 1981
A;Title: DNA sequence of two closely linked human leukocyte interferon genes.
A;Reference number: A94255; MUID:81201124; PMID:6165082
A;Accession: A01835
A;Molecule type: DNA
A;Residues: 1-189 <LAW>
A;Cross-references: UNIPROT:P01571; UNIPARC:UPI00000141F4B; GB:J00216; GB:V00532; NID:g32
R;Mizoguchi, J.; Pittha, P.M.; Raj, N.B.K.
DNA 4, 221-232, 1985
A;Title: Efficient expression in Escherichia coli of two species of human interferon- α
A;Reference number: A22255; MUID:85229953; PMID:3891272
A;Accession: A22255
A;Molecule type: mRNA
A;Residues: 1-56, 'H', 58-189 <MIZ>
A;Cross-references: UNIPARC:UPI0000052AF9; GB:M11026; NID:g184612; PIDN:AAA52725.1; PID:
R;Zoon, K.C.; Miller, D.; Bekisz, J.; zur Nedden, D.; Enterline, J.C.; Nguyen, N.Y.; Hu,
J. Biol. Chem. 267, 15210-15216, 1992
A;Title: Purification and characterization of multiple components of human lymphoblastoid
A;Reference number: A42753; MUID:92340576; PMID:1634550
A;Accession: C42753
A;Molecule type: protein
A;Residues: 'X', 25-50, 'XX', 53-56 <ZOO>
A;Cross-references: UNIPARC:UPI000017365F
C;Genetics:
A;Gene: GDB:IFNA17
A;Cross-references: GDB:136358; OMIM:147583
A;Map position: 9p22-9p22
C;Superfamily: interferon alpha
C;Keywords: leukocyte
F;1-23/Domain: signal sequence #status predicted <SIG>
F;24-189/Product: interferon alpha-17 #status predicted <MAT>
F;24-122, 52-162/Disulfide bonds: #status predicted

Query Match 79.2%; Score 760.5; DB 1; Length 189;
Best Local Similarity 79.9%; Pred. No. 5.3e-63;
Matches 151; Conservative 17; Mismatches 20; Indels 1; Gaps 1;

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTLMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALSFSLLMAVLLVLSYKSICSLGCDLPQTHSLGNRRALITLLAQMGRISPSFCLKDRPDPG 60
QY 61 FPQEEF-GNQFQKAETIPVLHEMIOQIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLE 119
Db 61 LPQEEFDGNQFQKAISVLHEMIOQTENLSTEDSSAAWEGSLLEKFESTELYYQQLNDLE 120

QY 120 ACVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAWEVVRRAEIMRSFSLSTN 179
Db 121 ACVIQEVGEETPLMNVDSILAVRKYFORITLLYLTEKKYSPCAWEVVRRAEIMRSLSFSTN 180
QY 180 LQESLRSKE 188
Db 181 LQKILRRKD 189

RESULT 15
137584
IFN-alpha-N-protein - human
C;Species: Homo sapiens (man)
C;Date: 04-Oct-1996 #sequence_revision 04-Oct-1996 #text_change 09-Jul-2004
C;Accession: I37584
R;Gren, E.Y.; Berzin, V.M.; Tsimanis, A.Y.; Apsalon, U.R.; Vishnevskii, Y.I.; Yansone, I.
.A.; Lozha, V.P.; Kavan, V.M.; Efimov, V.A.; Sverdlov, E.D.
Dokl. Biochem. 269, 91-95, 1983
A;Title: A new type of leukocytic interferon.
A;Reference number: I37583
A;Accession: I37584
A;Status: preliminary; translated from GB/EMBL/DBJ
A;Molecule type: mRNA
A;Residues: 1-189 <RES>
A;Cross-references: UNIPROT:Q14618; UNIPARC:UPI0000072A39; EMBL:X00140; NID:g32726; PIDN:
C;Superfamily: interferon alpha

Query Match 78.8%; Score 756.5; DB 2; Length 189;
Best Local Similarity 79.9%; Pred. No. 1.2e-62;
Matches 151; Conservative 12; Mismatches 25; Indels 1; Gaps 1;

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTLMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MPLSFSLLMAVLLVLSYKSICSLGCDLPQTHSLGNRRAWITLLAQMGRISHFSCLKDRYDFG 60
QY 61 FPQEEF-GNQFQKAETIPVLHEMIOQIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLE 119
Db 61 FPQEEFDGNQFQKAISAFHEMIOQTENLSTKSSAAWDETLDDKFTYELYYQQLNDLE 120
QY 120 ACVIQGVGTETPLMKEDSILAVRKYFORITLLYLKEKKYSPCAWEVVRRAEIMRSFSLSTN 179
Db 121 ACVIQEVGEETPLMNVDSILAVRKYFORITLLYLMGKKYSPCAWEVVRRAEIMRSFSLSTN 180
QY 180 LQESLRSKE 188
Db 181 LQKGLRRKD 189

Search completed: October 14, 2006, 08:02:36
Job time : 42 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: October 14, 2006, 07:53:27 ; Search time 301 Seconds
(without alignments)
577.751 Million cell updates/sec

Title: US-10-653-350-1
Perfect score: 960
Sequence: 1 MALTFALLVALVLVLSCKSSC.....EIMRSFSLSTNQESLRSKE 188

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 2849598 seqs, 925015592 residues

Total number of hits satisfying chosen parameters: 2849598

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : UniProt 7.2:*
1: uniprot_sprot:*
2: uniprot_trembl:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	960	100.0	188	2 Q6DJX8_HUMAN	Q6djx8 homo sapien
2	957	99.7	188	1 IFNA2_HUMAN	P01563 homo sapien
3	851	88.6	166	2 Q86UP4_HUMAN	Q86up4 homo sapien
4	814.5	84.8	189	2 Q95J78_SAGOE	Q95j78 saguinus oe
5	809.5	84.3	189	1 IFNA5_HUMAN	P01569 homo sapien
6	809.5	84.3	189	2 Q521X3_HUMAN	Q521x3 homo sapien
7	808.5	84.2	189	1 IFNA6_HUMAN	P05013 homo sapien
8	808.5	84.2	189	2 Q5VYQ1_HUMAN	Q5vyq1 homo sapien
9	793.5	82.7	189	1 IFNA14_HUMAN	P01570 homo sapien
10	793.5	82.7	189	2 Q5VZ56_HUMAN	Q5vz56 homo sapien
11	789.5	82.2	189	2 Q95J77_SAGOE	Q95j77 saguinus oe
12	786	81.9	154	2 Q6QNB6_HUMAN	Q6qnb6 homo sapien
13	781.5	81.4	189	1 IFNA4_HUMAN	P05014 homo sapien
14	781.5	81.4	189	2 Q5VV15_HUMAN	Q5vv15 homo sapien
15	776.5	80.9	189	2 Q521B8_HUMAN	Q521b8 homo sapien
16	772.5	80.5	189	1 IFNA1_HUMAN	P01562 homo sapien
17	772.5	80.5	189	2 Q2M1L8_HUMAN	Q2m1l8 homo sapien
18	770.5	80.3	189	1 IFNA17_HUMAN	P01571 homo sapien
19	770.5	80.3	189	2 Q5VZ53_HUMAN	Q5vz53 homo sapien
20	768.5	80.1	189	1 IFNA21_HUMAN	P01568 homo sapien
21	768.5	80.1	189	2 Q5VWD1_HUMAN	Q5vwd1 homo sapien
22	767.5	79.9	189	1 IFNA16_HUMAN	P05015 homo sapien
23	767.5	79.9	189	2 Q5VV12_HUMAN	Q5vv12 homo sapien
24	766.5	79.8	189	1 IFNA10_HUMAN	P01566 homo sapien
25	766.5	79.8	189	2 Q5VV13_HUMAN	Q5vv13 homo sapien
26	760.5	79.2	174	2 Q8MUT1_SAISSC	Q8mut1 salmirl sci
27	756.5	78.8	189	2 Q14618_HUMAN	Q14618 homo sapien
28	754.5	78.6	189	1 IFNA8_HUMAN	P32881 homo sapien
29	754.5	78.6	189	2 Q5VYQ3_HUMAN	Q5vyq3 homo sapien
30	744.5	77.6	189	1 IFNA7_HUMAN	P01567 homo sapien
31	744.5	77.6	189	2 Q5VV14_HUMAN	Q5vv14 homo sapien

32	739.5	77.0	181	2 Q14608_HUMAN	Q14608 homo sapien
33	722.5	75.3	184	1 IFNA4_HORSE	P05006 equus cabal
34	718.5	74.8	184	1 IFNA2_HORSE	P05004 equus cabal
35	710.5	74.0	184	1 IFNA3_HORSE	P05005 equus cabal
36	704.5	73.4	184	1 IFNA1_HORSE	P05003 equus cabal
37	677.5	70.6	166	2 Q8WZ68_HUMAN	Q8wz68 homo sapien
38	640.5	66.7	189	1 IFNA1_PIG	P49879 sus scrofa
39	637.5	66.4	189	2 Q304W3_PIG	Q304w3 sus scrofa
40	637.5	66.4	189	2 Q6VAB8_PIG	Q6vab8 sus scrofa
41	631.5	65.8	189	2 Q304V9_PIG	Q304v9 sus scrofa
42	625.5	65.2	181	2 Q304W4_PIG	Q304w4 sus scrofa
43	622.5	64.8	189	2 Q304W5_PIG	Q304w5 sus scrofa
44	616.5	64.2	181	2 Q304W0_PIG	Q304w0 sus scrofa
45	611.5	63.7	189	2 Q68IQ5_PIG	Q68iq5 sus scrofa

ALIGNMENTS

RESULT 1
Q6DJX8_HUMAN PRELIMINARY; PRT; 188 AA.
ID Q6DJX8_HUMAN
AC Q6DJX8;
DT 10-MAY-2005, integrated into UniProtKB/TrEMBL.
DT 10-MAY-2005, sequence version 1.
DT 21-FEB-2006, entry version 13.
DE Interferon, alpha 2 (IFNA2 protein).
GN Name=IFNA2; ORFNames=RP11-354P17.2-001;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones, and Pooled tissue;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Bhat N.K.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Hsieh F.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahay J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Pooled tissue;
RG NIH MGC Project;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
RN [3]
RP NUCLEOTIDE SEQUENCE.
RA Halleck A., Ebert L., Mkandinya M., Schick M., Eisenstein S.,
RA Neubert P., Kstrang K., Schatten R., Shen B., Henze S., Mar W.,
RA Korn B., Zuo D., Hu Y., Labber J.;
RL Submitted (JUN-2004) to the EMBL/GenBank/DBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE.
RA Beasley H.;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
RN [5]

RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RG NIH MGC Project;
RL Submitted (SEP-2005) to the EMBL/GenBank/DBJ databases.
CC -I- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; BC074937; AAH74937.1; -; mRNA.
DR EMBL; CR541921; CAG46719.1; -; mRNA.
DR EMBL; AL353732; CAH72906.1; -; Genomic DNA.
DR EMBL; BC104164; AA104165.1; -; mRNA.
DR EMBL; BC074936; AAH74936.1; -; mRNA.
DR EMBL; BC104163; AA104164.1; -; mRNA.
DR SMR; Q6DUX8; 24-188.
DR Ensembl; ENSG00000188379; Homo sapiens.
DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR SMART; SM00076; Ifabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine.
SQ SEQUENCE 188 AA; 21578 MW; 9BAA21D2BFB421D CRC64;

Query Match 100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 6.5e-78;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTPALLVALLVLSCKSSCSVGCDDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
DB 1 MALTPALLVALLVLSCKSSCSVGCDDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHMIQQIFNLSTKSSAAMDETLDKFTYELYYQQLNDLEA 120
DB 61 FPQEEFGNQFQKAETIPVLHMIQQIFNLSTKSSAAMDETLDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVVTEPTPLMKEDSILAVRKYFORITLLYLKEKKYSPCAWEVYRAEIMRSFSLSTNL 180
DB 121 CVIQGVVTEPTPLMKEDSILAVRKYFORITLLYLKEKKYSPCAWEVYRAEIMRSFSLSTNL 180
QY 181 QESLRKE 188
DB 181 QESLRKE 188

RESULT 2
ID IFNA2 HUMAN STANDARD; PRT; 188 AA.
AC P01563; P01564; Q14606; Q96K16;
DT 21-JUL-1986; Integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986; sequence version 1.
DT 07-FEB-2006; entry version 67.
DE Interferon alpha-2 precursor (Interferon alpha-A) (leif A).
GN Name=IFNA2;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
OX NCB1_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81052322; PubMed=6159538;
RA Goeddel D.V., Yelverton E., Ullrich A., Heyneker H.L., Miozzari G.,
RA Holmes W., Seeburg P.H., Dull T.J., May L., Stebbing N., Crea R.,
RA Maeda S., McCandliss R., Sloma A., Tabor J.M., Gross M.,
RA Familletti P.C., Pestka S.;
RT "Human leukocyte interferon produced by E. coli is biologically

RT active.";
RL Nature 287:411-416(1980).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81148795; PubMed=6163083;
RA Goeddel D.V., Leung D.W., Dull T.J., Gross M., Lawn R.M.,
RA McCandliss R., Seeburg P.H., Ullrich A., Yelverton E., Gray P.W.;
RT "The structure of eight distinct cloned human leukocyte interferon
cDNAs.";
RL Nature 290:20-26(1981).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=82060261; PubMed=6170983;
RA Lawn R.M., Gross M., Houck C.M., Franke A.E., Gray P.V., Goeddel D.V.;
RT "DNA sequence of a major human leukocyte interferon gene.";
RL Proc. Natl. Acad. Sci. U.S.A. 78:5435-5439(1981).
RN [4]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Bone marrow tumor;
RX MEDLINE=86069501; PubMed=3906813;
RA Oliver G., Balbas P., Valle F., Soberon X., Bolivar F.;
RT "Cloning of human leukocyte interferon cDNA and a strategy for its
production in E. coli.";
RL Rev. Latinoam. Microbiol. 27:141-150(1985).
RN [5]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=Placenta;
RX MEDLINE=98357449; PubMed=9694076;
RA Austriy E., Bagnis C., Carbuccia N., Maroc C., Birg F., Dubreuil P.,
RA Mannoni P., Chabannon C.;
RT "A defective retroviral vector encoding human interferon alpha 2 can
transduce human leukemic cell lines.";
RL Cancer Gene Ther. 5:247-256(1998).
RN [6]
RP NUCLEOTIDE SEQUENCE OF 7-188.
RX MEDLINE=81015442; PubMed=6158094;
RA Streuli M., Nagata S., Weissmann C.;
RT "At least three human type alpha interferons: structure of alpha 2.";
RL Science 209:1343-1347(1980).
RN [7]
RP NUCLEOTIDE SEQUENCE OF 24-188.
RX MEDLINE=83299241; PubMed=6310510;
RA Weber H., Weissmann C.;
RT "Formation of genes coding for hybrid proteins by recombination
between related, cloned genes in E. coli.";
RL Nucleic Acids Res. 11:5661-5669(1983).
RN [8]
RP PROTEIN SEQUENCE OF 24-112 AND 136-188.
RX MEDLINE=81052321; PubMed=6159537;
RA Allen G., Fantes K.H.;
RT "A family of structural genes for human lymphoblastoid (leukocyte-
type) interferon.";
RL Nature 287:408-411(1980).
RN [9]
RP PROTEIN SEQUENCE OF 24-58.
RX MEDLINE=98087498; PubMed=9425112;
RA Nyman T.A., Toeloe H., Parkkinen J., Kalkkinen N.;
RT "Identification of nine interferon-alpha subtypes produced by Sendai
virus-induced human peripheral blood leucocytes.";
RL Biochem. J. 329:295-302(1998).
RN [10]
RP DISULFIDE BONDS.
RX MEDLINE=81123083; PubMed=6162107;
RA Wetzel R.;
RT "Assignment of the disulphide bonds of leukocyte interferon.";
RL Nature 289:606-607(1981).
RN [11]
RP CARBOHYDRATE-LINKAGE SITE THR-129, AND VARIANTS ALPHA-2B AND ALPHA-2C.
RX MEDLINE=91264809; PubMed=2049076;
RA Adolf G.R., Kalsner I., Ahorn H., Maurer-Fogy I., Cantell K.;
RT "Natural human interferon-alpha 2 is O-glycosylated.";
RL Biochem. J. 276:511-518(1991).
RN [12]

RP POLYMORPHISM.
RX MEDLINE=95353982; PubMed=7627809;
RA Lee N., Ni D., Brissette R., Chou M., Hussain M., Gill D.S.,
RA Liao M.-J., Testa D.;
RT "Interferon-alpha 2 variants in the human genome.";
RL J. Interferon Cytokine Res. 15:341-349(1995).
RN [13]
RP 3D-STRUCTURE MODELING.
RX MEDLINE=94052087; PubMed=8234245; DOI=10.1002/prot.340170109;
RA Murgolo N.J., Windsor W.T., Hruza A., Reichert P., Tsaropoulos A.,
RA Baldwin S., Huang E., Pramanik B., Balick S., Trotta P.P.;
RT "A homology model of human interferon alpha-2.";
RL Proteins 17:62-74(1993).
RN [14]
RP X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS).
RX MEDLINE=97148339; PubMed=8994971; DOI=10.1016/S0969-2126(96)00152-9;
RA Radhakrishnan R., Walter L.J., Hruza A., Reichert P., Trotta P.P.,
RA Nagabhushan T.L., Walter M.R.;
RT "Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray
crystallography.";
RL Structure 4:1453-1463(1996).
RN [15]
RP STRUCTURE BY NMR.
RX MEDLINE=98118493; PubMed=9417943; DOI=10.1006/jmbi.1997.1396;
RA Klaus W., Gsell B., Labhardt A.M., Wipf B., Senn H.;
RT "The three-dimensional high resolution structure of human interferon
alpha-2a determined by heteronuclear NMR spectroscopy in solution.";
RL J. Mol. Biol. 274:661-675(1997).
CC -I- FUNCTION: Produced by macrophages, IFN-alpha have antiviral
activities. Interferon stimulates the production of two enzymes: a
protein kinase and an oligoadenylate synthetase.
CC -I- SUBCELLULAR LOCATION: Secreted protein.
CC -I- POLYMORPHISM: Three forms exist; alpha-2a (shown here), alpha-2b
and alpha-2c.
CC -I- PHARMACEUTICAL: Available under the names Roferon-A (Roche) or
interon-A (Schering-Plough). Used as an anticancer drug for its
antiproliferative activity.
CC -I- SIMILARITY: Belongs to the alpha/beta interferon family.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NonDerivs License
CC -----
DR EMBL; J00207; AAB59402.1; -; Genomic_DNA.
DR EMBL; V00544; CAA23805.1; -; mRNA.
DR EMBL; V00548; CAA23809.1; -; mRNA.
DR EMBL; V00549; CAA23810.1; -; mRNA.
DR EMBL; Y11834; CAA72532.1; -; Genomic_DNA.
DR EMBL; M54886; AAA59181.1; -; mRNA.
DR EMBL; M29883; AAA52715.1; -; Genomic_DNA.
DR EMBL; A04970; CAA00410.1; -; Unassigned_DNA.
DR PIR; A93234; IVHUA2.
DR PIR; I78570; I78570.
DR PDB; 1ITF; NMR; @=24-188.
DR PDB; 1RH2; X-ray; A/B/C/D/E/F=24-188.
DR PDB; 2HIE; Model; @=24-188.
DR GlycoSuiteDB; P01563; -;
DR Ensembl; ENSG00000188379; Homo sapiens.
DR HGNC; HGNC:5423; IFNA2.
DR MIM; 147562; gene.
DR LinkHub; P01563; -;
DR GO; GO:0005132; F:interferon-alpha/beta receptor binding; TAS.
DR GO; GO:0007166; P:cell surface receptor linked signal transdu. . .; TAS.
DR GO; GO:0007267; P:cell-cell signaling; TAS.
DR GO; GO:0006917; P:induction of apoptosis; TAS.
DR GO; GO:0006954; P:inflammatory response; TAS.
DR InterPro; IPR000471; Interferon abd.
DR PANTHER; PTHR11691; Interferon abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW 3D-structure; Antiviral defense; Cytokine; Direct protein sequencing;

KW Glycoprotein; Pharmaceutical; Polymorphism; Signal.
FT SIGNAL 1 23
FT CHAIN 24 188 Interferon alpha-2.
FT CARBOHYD 129 129 /FTid=PRO_0000016360.
FT DISULFID 24 121 O-1-linked (GalNAc. . .).
FT DISULFID 52 161 /FTid=CAR_000049.
FT VARIANT 46 46
FT VARIANT 57 57
FT HELIX 33 44
FT TURN 49 54
FT HELIX 63 66
FT HELIX 76 91
FT HELIX 93 98
FT HELIX 101 123
FT TURN 126 127
FT TURN 133 133
FT HELIX 134 155
FT TURN 156 157
FT HELIX 160 178
FT TURN 179 182
SQ SEQUENCE 188 AA; 21550 MW; 101DD21D394CBF97 CRC64;
Query Match 99.7%; Score 957; DB 1; Length 188;
Best Local Similarity 99.5%; Pred. No. 1.2e-77;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 MALTFALLVALIVLSCKSSGVGCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
DB 1 MALTFALLVALIVLSCKSSGVGCDLPQTHSLGSRRTMLLAQMRKISLFSCLKDRHDFG 60
QY 61 FPQEFNGQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLLDKFYTELQQLNDLEA 120
DB 61 FPQEFNGQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLLDKFYTELQQLNDLEA 120
QY 121 CVIQGVVTEPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAEIMRSFSLSTNL 180
DB 121 CVIQGVVTEPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
DB 181 QESLSRKE 188
RESULT 3
ID Q86UP4 HUMAN PRELIMINARY; PRT; 166 AA.
AC Q86UP4;
DT 01-JUN-2003, integrated into UniProtKB/TrEMBL.
DT 01-JUN-2003, sequence version 1.
DT 21-FEB-2006, entry version 13.
DE Interferon alpha 2b.
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Chikara S.K., Joseph B., Sharma G.;
RL Submitted (MAR-2003) to the EMBL/GenBank/DBJ databases.
CC -I- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NonDerivs License
CC -----
DR EMBL; AY255838; AAP20099.1; -; mRNA.
DR HSSP; P01563; 1ITF.
DR SMR; Q86UP4; 2-166.
DR Ensembl; ENSG00000188379; Homo sapiens.

DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine.
SQ SEQUENCE 166 AA; 19400 MW; B7DAC3C9E67782C6 CRC64;

Query Match 88.6%; Score 851; DB 2; Length 166;
Best Local Similarity 100.0%; Pred. No. 3.4e-68;
Matches 165; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 24 CDLPQTHSLGSRRTIMLLAQMRRIISLFSGLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI 83
Db 2 CDLPQTHSLGSRRTIMLLAQMRRIISLFSGLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI 61
QY 84 QQIFNLSTKSSAAMDETLDDKFTYELVQQLNDLEACVIGVGVTETPLMKEDSILAVR 143
Db 62 QQIFNLSTKSSAAMDETLDDKFTYELVQQLNDLEACVIGVGVTETPLMKEDSILAVR 121
QY 144 KYFORITLVLEKKYSPCAMEVVRRAIMRSFSLSTNLQESLSRKE 188
Db 122 KYFORITLVLEKKYSPCAMEVVRRAIMRSFSLSTNLQESLSRKE 166

RESULT 4

Q95J78_SAGOE PRELIMINARY; PRT; 189 AA.
Q95J78;
01-DEC-2001, integrated into UniProtKB/TrEMBL.
01-DEC-2001, sequence version 1.
21-FEB-2006, entry version 18.
DE Interferon-alpha precursor.
GN Name=Ifn-alpha;
OS Saguinus oedipus (Cotton-top tamarin).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Platyrrhini;
OC Callitrichidae; Saguinus.
OX NCBI_TaxID=9490;
RN [1]
RP NUCLEOTIDE SEQUENCE.

RA Ceccacci A., Aurisicchio L., Ciliberto G., Palombo F., Traboni C.;
RT "Recombinant cotton-top tamarin interferon: a new tool for a primate
hepatitis model".
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
CC -1- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs license
CC -----
CC
DR EMBL; AJ250195; CAC44124.1; -; Genomic_DNA.
DR HSSP; P01563; IITF.
DR SMR; Q95J78; 24-189.
DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine; Signal.
FT SIGNAL 1 23 Potential.
FT CHAIN 24 189 Potential.

SQ SEQUENCE 189 AA; 21937 MW; 06A45DD2B631C85C CRC64;

Query Match 84.8%; Score 814.5; DB 2; Length 189;
Best Local Similarity 86.2%; Pred. No. 7.5e-65;
Matches 163; Conservative 9; Mismatches 16; Indels 1; Gaps 1;

QY 1 MALTEALLVALVLSCKSGCVGCDLPQTHSLGSRRTIMLLAQMRRIISLFSGLKDRHDFG 60
Db 1 MTLTFPLVALVLVLSYKSGCGLGCDLPQTHSLGNRRITMLLAQMRRIISFSLKDRDFE 60
QY 61 FPQEEF-GNQFQKAETIPVLHEMIQQIFNLSTKSSAAMDETLDDKFTYELVQQLNDLE 119
Db 61 FPQEEFDGNQFQKARAFVLHEMIQQTFNLSTKSSAAMDETLDDKFTYELVQQLNELE 120
QY 120 ACVIGVGVTETPLMKEDSILAVRKYFORITLVLEKKYSPCAMEVVRRAIMRSFSLSTN 179
Db 121 ACVIGVGVTETPLMKEDSILAVRKYFORITLVLEKKYSPCAMEVVRRAIMRSFSLSTN 180
QY 180 LQESLSRKE 188
Db 181 LQKGLRSKK 189

RESULT 5

IFN55_HUMAN STANDARD; PRT; 189 AA.
IFN55_HUMAN
P01565;
21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
13-AUG-1987, sequence version 1.
07-FEB-2006, entry version 57.
DE Interferon alpha-5 precursor (Interferon alpha-G) (leIF G) (Interferon
alpha-61).
GN Name=IFN55;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86037205; Pubmed=4057246;
RA Henco K., Brosius J., Fujisawa A., Fujisawa J., Haynes J.R.,
RA Hochstadt J., Kovacic T., Pasek M., Schamboeck A., Schmid J.,
RA Todokoro K., Waelchli M., Nagata S., Weissmann C.;
RT "Structural relationship of human interferon alpha genes and
pseudogenes.";
RL J. Mol. Biol. 185:227-260(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX Pubmed=15164053; DOI=10.1038/nature02465;
RA Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA Babage A.K., Babage S., Bagguley C.L., Bailey J., Banerjee R.,
RA Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA Cummings A.T., Davies J., Dhani P., Dunn M., Dutta I., Dyer L.W.,
RA Barthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA Frankland J.A., French L., Fricke D.G., Garner P., Garnett J.,
RA Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA McIay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,

```

RA Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.,
RA Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA Rogers J., Dunham I.,
RT "DNA sequence and analysis of human chromosome 9.";
RL Nature 429:369-374(2004).
RN [3]
RP NUCLEOTIDE SEQUENCE OF 57-189.
RC TISSUE=Spleen;
RX MEDLINE=1148795; PubMed=6163083;
RA Goeddel D.V., Leung D.W., Dull T.J., Gross M., Lawn R.M.,
RA McCandless R., Seeburg P.H., Ullrich A., Yelverton E., Gray P.W.;
RT "The structure of eight distinct cloned human leukocyte interferon
RT cDNAs.";
RL Nature 290:20-26(1981).
RN [4]
RP PROTEIN SEQUENCE OF 22-36.
RX PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally
RT verified cleavage sites.";
RL Protein Sci. 13:2819-2824(2004).
CC -!- FUNCTION: Produced by macrophages, IFN-alpha have antiviral
CC activities. Interferon stimulates the production of two enzymes: a
CC protein kinase and an oligoadenylate synthetase.
CC -!- SUBCELLULAR LOCATION: Secreted protein.
CC -!- SIMILARITY: Belongs to the alpha/beta interferon family.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs license
CC -----
CC EMBL: X02956; CAA26702.1; -; Genomic DNA.
CC EMBL: AL162420; CAH73189.1; -; Genomic DNA.
CC EMBL: V00541; CAA23802.1; -; mRNA.
CC PIR: S43716; IVHUA7.
CC HSSP: P01563; 1ITF.
CC SMR: P01569; 24-189.
CC DR Ensembl: ENSG00000147873; Homo sapiens.
CC DR HGNC: HGNC:5426; IFNA5.
CC DR MIM: 147565; gene.
CC LinkHub: P01569; -.
CC GO: GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; TAS.
CC InterPro: IPR000471; Interferon abd.
CC PANTHER: PTHR1691; Interferon_abd; 1.
CC Pfam: PF00143; Interferon; 1.
CC PRINTS: PR00266; INTERFERONAB.
CC PRODOM: PD000550; Interferon_abd; 1.
CC SMART: SM00076; IFabd; 1.
CC DR PROSITE: PS00252; INTERFERON_A_B_D; 1.
CC Antiviral defense; Cytokine; Direct protein sequencing; Signal.
KM SIGNAL 1 21
FT CHAIN 22 189 Interferon alpha-5.
FT /FTid=PRO_0000016362.
FT DISULFID 24 122 By similarity.
FT DISULFID 52 162 By similarity.
SQ SEQUENCE 189 AA; 21942 MW; C605992FE2E78043 CRC64;

Query Match 84.3%; Score 809.5; DB 1; Length 189;
Best Local Similarity 83.6%; Pred. No. 2,1e-64;
Matches 158; Conservative 11; Mismatches 19; Indels 1; Gaps 1

QY 1 MALTFALLVALVLVLSCKSSCSVGCDDLPTQTHSLGSRRTLMLLAQMRRIISFLSCLKDRHDFG 60
QY ||| ||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
DB 1 MALPFLVLMALVVLNCKSICSLGCDLPQTHSLSNRRITLMIAQMGRISPFSCLDRHDFG 60

QY 61 PPOEEF-GNQFOKAETIPVLHEMIQOIFNLFSTKDSAAWDETLLDKFYTELXQOINDLE 119
QY ||||| ||||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
DB 61 PPOEEFDGNQFOKAQAISVLHEMIQOTFNLFSKDSATWDETLLDKFYTELXQOINDLE 120
DB ||||| ||||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :||| :|||
QY 120 ACVIGVGTETPLMKEDSILAVRKYFORITLYLEKKYSPCAMEVVRAEIMRSFSISTN 179
QY ||:| ||| ||| :||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |

```

```

Db      121 ACMMQEVGVEDTPLMNVDSILTVRKYFORITLYLTEKYPSCAMEVVRAEIMRSFSLSAN 180
QY      180 LQESLRKE 188
          ||| |||
Db      181 LQERLRKE 189

RESULT 6
Q52LX3 HUMAN
ID      Q52LX3 HUMAN PRELIMINARY; PRT; 189 AA.
AC      Q52LX3;
DT      24-MAY-2005, integrated into UniProtKB/TrEMBL.
DT      24-MAY-2005, sequence version 1.
DT      21-FEB-2006, entry version 9.
DE      Interferon, alpha 5.
GN      Name=IFNA5;
OS      Homo sapiens (Human).
OC      Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC      Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC      Homo.
OX      NCBI_TaxID=9606;
RN      [1]
RP      NUCLEOTIDE SEQUENCE.
RC      TISSUE=Brain;
RX      MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA      Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA      Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA      Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA      Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA      Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA      Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA      Brownstein M.J., Usdin T.B., Toshiyuki S., Abramson R.D., Prange C.,
RA      Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Prange C.,
RA      Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA      Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA      Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA      Fahey J., Helton E., Kettman M., Madan A., Rodriguez S., Sanchez A.,
RA      Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA      Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA      Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA      Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA      Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT      "Generation and initial analysis of more than 15,000 full-length human
RT      and mouse cDNA sequences."
RT      Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN      [2]
RP      NUCLEOTIDE SEQUENCE.
RC      TISSUE=Brain;
RG      NIH MGC Project;
RL      Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
CC      -1- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC      -----
CC      Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC      Distributed under the Creative Commons Attribution-NonDerivs license
CC      -----
CC      EMBL; BC093757; AAH93757.1; -; mRNA.
CC      EMBL; BC093755; AAH93755.1; -; mRNA.
CC      SMR; Q52LX3; 24-189.
DR      Ensemble; ENSG00000147873; Homo sapiens.
DR      GO; GO:0005615; C:extracellular space; IEA.
DR      GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR      GO; GO:0006952; P:defense response; IEA.
DR      GO; GO:0009615; P:response to virus; IEA.
DR      InterPro; IPR000471; Interferon abd.
DR      PANTHER; PTHR11691; Interferon_abd; 1.
DR      Pfam; PF00143; Interferon; 1.
DR      PRINTS; PR00266; INTERFERONAB.
DR      ProDom; PD000550; Interferon_abd; 1.
DR      SMART; SM00076; IFabd; 1.
DR      PROSITE; PS00252; INTERFERON_A_B_D; 1.
DR      Antiviral defense; Cytokine.
DR      SEQUENCE 189 AA; 21942 MW; C605992FE2E78043 CRC64;

```

```

Query Match          84.3%; Score 809.5; DB 2; Length 189;
Best Local Similarity 83.6%; Pred. No. 2.1e-64;
Matches 158; Conservative 11; Mismatches 19; Indels 1; Gaps 1;

OY 1 MALTFALLVALVLVLSCKSSCSVSCDLPQTHSLGSRRTMLLAQMRRLSFLSCLKDRHDFG 60
   |||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 1 MALPFVLLMALVNLCKSSICSGCDLPQTHSLSNRRTLMIMAGMRISPFSCDKDRHDFG 60

OY 61 FPOEEF-GNOFOKAETIPVLHEMIOIIFNLSTKDDSSAAMDFTLLDKFYTELXQQLNDLE 119
   |||||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 61 FPOEEFDGNOFOKAQAIISVLHEMIOOTFNLSTKDDSSATWDETLLDKFYTELXQQLNDLE 120

OY 120 ACVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTN 179
   ||::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|::|
Db 121 ACWMOEVGVEDTPLMNVDLSILVRYKFORITLYLTKKYSPCAEWVVRRAEIMRSFSLSAN 180

OY 180 LQESLRKE 188
   ||| |||
Db 181 LQERLRKE 189

RESULT 7
IFNA6_HUMAN
ID IFNA6_HUMAN STANDARD; PRT; 189 AA.
AC P05013;
DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT 13-AUG-1987, sequence version 1.
DT 07-FEB-2006, entry version 58.
DE Interferon alpha-6 precursor (Interferon alpha-K) (leif K) (Interferon
DE alpha-54).
DE Name=IFNA6;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homiidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86037205; PubMed=4057246;
RA Henco K., Brosius J., Fujisawa A., Fujisawa J., Haynes J.R.,
RA Hochstadt J., Kovacic T., Pasek M., Schamboeck A., Schmid J.,
RA Todokoro K., Waelchli M., Nagata S., Weissmann C.;
RT "Structural relationship of human interferon alpha genes and
RT pseudogenes.";
RL J. Mol. Biol. 185:227-260(1985).
RN [2]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettman M., Madan A., Rodrigues S., Sanchez A.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickinson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Buterfield Y.S.N., Krzywinski M.I., Skalska U., Smalhus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP PROTEIN SEQUENCE OF 21-35.
RX PubMed=15340161; DOI=10.1110/ps.04682504;
RA Zhang Z., Henzel W.J.;
RT "Signal peptide prediction based on analysis of experimentally

```

```

RT verified cleavage sites."
RL Protein Sci.13:2819-2824(2004).
CC -|- FUNCTION: Produced by macrophages, IFN-alpha have antiviral
CC activities. Interferon stimulates the production of two enzymes: a
CC protein kinase and an oligoadenylate synthetase.
CC -|- SUBCELLULAR LOCATION: Secreted protein.
CC -|- SIMILARITY: Belongs to the alpha/beta interferon family.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NonDerivs License
CC -----
CC EMBL, X02958; CAA26704.1; -; Genomic_DNA.
DR EMBL, BC069471; AAH69471.1; -; mRNA.
DR PIR, A23753; IVHUI6.
DR HSSP, P01563; 1ITF.
DR SMR, P05013; 24-189.
DR Ensembl, ENSG00000120235; Homo sapiens.
DR HGNC, HGNC:5427; IFNA6.
DR MIM, 147566; gene.
DR GO, GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; NAS
DR GO, GO:0009615; P:response to virus; NAS.
DR InterPro, IPR000471; Interferon_abd.
DR PANTHER, PTHR11691; Interferon_abd; 1.
DR Pfam, PF00143; Interferon; 1.
DR PRINTS, PR00266; INTERFERONAB.
DR ProDom, PD000550; Interferon_abd; 1.
DR SMART, SM00076; IFabd; 1.
DR PROSITE, PS00252; INTERFERON_A B D; 1.
DR Antiviral defense; Cytokine; Direct protein sequencing; Signal.
FT SIGNAL 1 20
FT CHAIN 21 189 Interferon alpha-6.
FT /FTId=PRO_0000016363.
FT DISULFID 24 122 By similarity.
FT DISULFID 52 162 By similarity.
FT SEQUENCE 189 AA; 22141 MW; 8C7F3F90F12C562E CRC64;
SQ

```

```

Query Match      84.2%; Score 808.5; DB 1; Length 189;
Best Local Similarity 85.7%; Pred. No. 2.6e-64;
Matches 162; Conservative 6; Mismatches 20; Indels 1; Gaps 1;

QY      1 MALTFALLVALVLVLSCKSSCSVGCDLPQTHSLGSRPTMLLAQMRRISLFSCLKDRHDFG 60
        ||| | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db      1 MALPFALLMALVVLSCSKSSCSLDCLDPLPQTHSLGHRTWMLLAQMRRISLFSCLKDRHDFR 60

QY      61 FPQEERF-GNQFOKAEITIPVLHEMIQQIFNLFSFKDSAAWDETLDDKFYTELYQQQLNDEL 119
        ||| | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |
Db      61 FPQEERFDGNQFOKAEISVLHEVIQQTFNLFSTKDSVAWDERLLDKLTETELYQQQLNDLE 120

QY      120 ACVIOGVGTETPLMKEDSILAVRKYPORITLYLKPKYSPPCAWEVVRAEIMRSFSLSTN 179
        ||| : | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Db      121 ACVMQEVWGVTPLMNEDSLAVRKYFORITLYLTEKKYSPCAWEVVRAEIMRSFSSGRN 180

QY      180 LQESLRKSKE 188
        ||| | | | | |

Db      181 LQERLRKE 189

RESULT 8
Q5VYQ1 HUMAN
ID Q5VYQ1 HUMAN PRELIMINARY; PRT; 189 AA.
AC Q5VYQ1;
DT 10-MAY-2005, integrated into UniProtKB/TREMBL.
DT 10-MAY-2005, sequence version 1.
DT 21-FEB-2006, entry version 10.
DE Interferon, alpha 6.
OS Name=IFNA6; ORFNames=RP11-354P17.7-001;
GN Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
```


RA Beasley H.;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butcherfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RG NIH MGC Project;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
RN [4]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RG NIH MGC Project;
RL Submitted (JUN-2005) to the EMBL/GenBank/DBJ databases.
CC -1- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
CC Distributed under the Creative Commons Attribution-NoDerivs license
CC -----
CC
CC EMBL; AL353732; CAH72903.1; -; Genomic_DNA.
CC
CC EMBL; BC096710; AAH96710.1; -; mRNA.
CC
CC EMBL; BC096730; AAH96730.1; -; mRNA.
CC
CC EMBL; BC098357; AAH98357.1; -; mRNA.
CC
CC EMBL; BC096697; AAH96697.1; -; mRNA.
CC
CC SMR; Q5VYQ1; 24-189.
CC
CC DR Ensembl; ENSG0000120235; Homo sapiens.
CC
CC DR GO; GO:0005615; C:extracellular space; IEA.
CC
CC DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
CC
CC DR GO; GO:0006952; P:defense response; IEA.
CC
CC DR GO; GO:0009615; P:response to virus; IEA.
CC
CC DR InterPro; IPR00471; Interferon_abd.
CC
CC DR PANTHER; PTHR11691; Interferon_abd; 1.
CC
CC DR Pfam; PF00143; Interferon; 1.
CC
CC DR PRINTS; PR00266; INTERFERONAB.
CC
CC DR SMART; SM00076; IFabd; 1.
CC
CC DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
CC
CC KW Antiviral defense; Cytokine.
CC
CC SQ SEQUENCE 189 AA; 22141 MW; 8C7F3F90F12C562E CRC64;
Query Match 84.2%; Score 808.5; DB 2; Length 189;
Best Local Similarity 85.7%; Pred. No. 2.6e-64;
Matches 162; Conservative 6; Mismatches 20; Indels 1; Gaps 1;

QY 1 MALTFAALLVLLVLSCKSSCGVCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
DB 1 MALPFAALLVLLVLSCKSSCSLDLCPQTHSLGHRRTMLLAQMRRISLFSCLKDRHDFR 60
QY 61 FPQEEF-GNQFQKAETIPVLHEMIOQIFNIFSTKSSAAMDETLLDKRYTELYQQLNDLE 119
DB 61 FPQEEFDGNQFQKAETISVLHEVIOQTFFNIFSTKSSVAVDERLLDKLYTELYQQLNDLE 120

QY 120 ACVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPECAWEVVAEIMRSFSLSTN 179
DB 121 ACVQGEVWVGCTPLMNEDSLAVRKYFORITLYLTEKYSPECAWEVVAEIMRSFSSSRN 180
QY 180 LQESLRSKE 188
DB 181 LQERLRKE 189
RESULT 9
ID IFN14 HUMAN STANDARD; PRT; 189 AA.
AC P01570;
DT 21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT 21-JUL-1986, sequence version 3.
DT 07-FEB-2006, entry version 63.
DE Interferon alpha-14 precursor (Interferon alpha-H) (LeIF H)
DE (Interferon lambda-2-H).
GN Name=IFNA14;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=86037205; PubMed=4057246;
RA Henco K., Brosius J., Fujisawa A., Fujisawa J., Haynes J.R.,
RA Hochstadt J., Kovacic T., Pasek M., Schamboeck A., Schmid J.,
RA Todokoro K., Waelchli M., Nagata S., Weissmann C.;
RT "Structural relationship of human interferon alpha genes and
RT pseudogenes.";
RL J. Mol. Biol. 185:227-260 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81201124; PubMed=6165082;
RA Lawn R.M., Adelman J., Dull T.J., Gross M., Goeddel D.V., Ullrich A.;
RT "DNA sequence of two closely linked human leukocyte interferon
RT genes.";
RL Science 212:1159-1162 (1981).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=81148795; PubMed=6163083;
RA Goeddel D.V., Leung D.W., Dull T.J., Gross M., Lawn R.M.,
RA McCandliss R., Seeburg P.H., Ullrich A., Yelverton E., Gray P.W.;
RT "The structure of eight distinct cloned human leukocyte interferon
RT cDNAs.";
RL Nature 290:20-26 (1981).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G., Schuler G.D.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Bhat N.K.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Hsieh F.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahy J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butcherfield Y.S.N., Krzywinski M.I., Skalska U., Smallus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [5]
RP PROTEIN SEQUENCE OF 24-53, AND CARBOHYDRATE-LINKAGE SITE ASN-95.

RX MEDLINE=98087498; PubMed=9425112;
RA Nyman T.A., Toeloe H., Parkkinen J., Kalkkinen N.;
RT "Identification of nine interferon-alpha subtypes produced by Sendai
RL virus-induced human peripheral blood leucocytes.";
RN Biochem. J. 329:295-302(1998).
RN [6]
RP ABSENCE OF POLYMORPHISM.
RX MEDLINE=97067358; PubMed=8910771;
RA Hussain M., Gull D.S., Liao M.-J.;
RT "Identification of interferon-alpha 7, -alpha 14, and -alpha 21
RT variants in the genome of a large human population.";
RL J. Interferon Cytokine Res. 16:853-859(1996).
CC -|- FUNCTION: Produced by macrophages, IFN-alpha have antiviral
CC activities. Interferon stimulates the production of two enzymes: a
CC protein kinase and an oligoadenylate synthetase.
CC -|- SUBCELLULAR LOCATION: Secreted protein.
CC -|- SIMILARITY: Belongs to the alpha/beta interferon family.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; V00533; CAA23794.1; -; Genomic DNA.
DR EMBL; X02959; CAA26705.1; -; Genomic DNA.
DR EMBL; V00542; CAA23803.1; -; mRNA.
DR EMBL; BC074956; AAH74956.1; -; mRNA.
DR PIR; A92916; IYHUL4.
DR HSSP; P01563; 1ITF.
DR SMR; P01570; 24-189.
DR GlycoSuiteDB; P01570; -.
DR HGNC; HGNC:5420; IFNA14.
DR MIM; 147579; Gene.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; TAS.
DR InterPro; IPR00471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; Ifabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine; Direct protein sequencing; Glycoprotein;
KW Signal.
KW SIGNAL.
FT CHAIN 1 23 Interferon alpha-14.
FT SIGNAL 24 189 /FTid=PRO_0000016367.
FT CARBOHYD 95 95 N-linked (GlcNAc. . .).
FT DISULFID 24 122 By similarity.
FT DISULFID 52 162 By similarity.
FT CONFLICT 175 175 L -> F (in Ref. 3).
SQ SEQUENCE 189 AA; 22063 MW; B6B71E2F0D644FE7 CRC64;

Query Match 82.7%; Score 793.5; DB 1; Length 189;
Best Local Similarity 82.0%; Pred. No. 5.8e-63;
Matches 155; Conservative 16; Mismatches 17; Indels 1; Gaps 1;

OY 1 MALTFALLVALLVLSCKSSGCVGCDLPQTHSLGSRRITMLLAQMRRISLFSCLKDRHDFG 60
DB 1 MALPFAIMMALVTLSCSSCSLGCNLSQTHSLNNRRITMLMAQMRRIISPFSCLKDRHDFE 60
OY 61 FPQEEF-GNQFOKAETIPVLHEMIOQIFNLSTKSSAAMDETLLDKRYTELXQQLNDLE 119
DB 61 FPQEEFDGNQFOKAQAISVLHEMIOQTFNLSTKSSAAMDETLLKRYIELFOQMDLLE 120
OY 120 ACVIOGVGVETETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVYRAEIMRSFSLSTN 179
DB 121 ACVIOGVGVETETPLMKEDSILAVRKYFORITLYLMEKYSPCAMEVYRAEIMRSLSFSTN 180
OY 180 LQESLSRKE 188
DB 181 LQKRLRRKD 189

RESULT 10
OSVZ56_HUMAN

ID OSVZ56_HUMAN PRELIMINARY; PRT; 189 AA.
AC OSVZ56;
DT 10-MAY-2005, integrated into UniProtKB/TrEMBL.
DT 10-MAY-2005, sequence version 1.
DT 21-FEB-2006, entry version 9.
DE Interferon, alpha 14 (IFNA14 protein).
GN Name=IFNA14; ORFNames=RP11-380P16.9-001;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Beasley H.;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Sherman C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Abramson R.D., Mullahy S.J.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullahy S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalon D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahney J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butterfield V.S.N., Krzyzinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences.";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
RN [3]
RP NUCLEOTIDE SEQUENCE.
RC TISSUE=PCR rescued clones;
RG NIH MGC Project;
CC Submitted (SEP-2005) to the EMBL/GenBank/DBJ databases.
CC -|- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
CC EMBL; AL162420; CAH73187.1; -; Genomic DNA.
DR EMBL; BC104159; AA104160.1; -; mRNA.
DR EMBL; BC104160; AA104161.1; -; mRNA.
DR SMR; OSVZ56; 24-189.
DR Ensembl; ENSG00000137026; Homo sapiens.
DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0006615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR SMART; SM00076; Ifabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine.
SQ SEQUENCE 189 AA; 22063 MW; B6B71E2F0D644FE7 CRC64;

Query Match 82.7%; Score 793.5; DB 2; Length 189;
Best Local Similarity 82.0%; Pred. No. 5.8e-63;
Matches 155; Conservative 16; Mismatches 17; Indels 1; Gaps 1;

OY 1 MALTFALLVALLVLSCKSSGCVGCDLPQTHSLGSRRITMLLAQMRRISLFSCLKDRHDFG 60

```
Db      1 MALPFRALMALVVLSCSSCSGLGUSQTHSLNNRRTLMMAQMRISPFSCDKDRHDFE 60
QY      61 FPGQEEF-GNQFOKAETIPVLHEMIQIIFNLFSTKSSAAWDETLIDKFYTELYQQLNDLE 119
Db      61 FPGQEEFDGNQFOKAQAISVLHEMIQOTFNLFSTKNSSAAWDETLIEKFYIELFOQLNDLE 120
QY      120 ACVIOGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTN 179
Db      121 ACVIOEVGVEETPLMNEDSILAVKCYFORITLYLMEKKYSPCAWEVVRRAEIMRSLSFSTN 180
QY      180 LQESLRSKE 188
Db      181 LQKRLRRKD 189
```

```
RESULT 11
Q95J77 SAGOE PRELIMINARY; PRT; 189 AA.
ID Q95J77 SAGOE
AC Q95J77
DT 01-DEC-2001, integrated into UniProtKB/TrEMBL.
DT 01-DEC-2001, sequence version 1.
DT 21-FEB-2006, entry version 18.
DE Interferon-alpha precursor.
GN Name=ifn-alpha;
OS Saguinus oedipus (Cotton-top tamarin).
OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Platyrrhini;
OC Callitrichidae; Saguinus.
OX NCBI_TaxID=9490;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Ceccacci A., Aurisicchio L., Ciliberto G., Palombo F., Traboni C.;
RT "Recombinant cotton-top tamarin interferon: a new tool for a primate
RT hepatitis model.";
RL Submitted (OCT-1999) to the EMBL/GenBank/DBJ databases.
CC -!- SUBCELLULAR LOCATION: Secreted protein (By similarity).
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AJ250196; CAC44125.1; -; Genomic_DNA.
DR HSSP; P01563; 1ITF.
DR SMR; Q95J77; 24-189.
DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine; Signal.
FT SIGNAL 1 23 Potential.
FT CHAIN 24 189 Interferon-alpha.
SQ SEQUENCE 189 AA; 22052 MW; 9E4389CFEC329DBA CRC64;
```

```
Query Match      82.2%; Score 789.5; DB 2; Length 189;
Best Local Similarity 84.1%; Pred. No. 1.3e-62;
Matches 159; Conservative 9; Mismatches 20; Indels 1; Gaps 1;
```

```
Db      121 ACVIOEVGVTDTPLNEDSILTVRKYFORITLYLKEKKYSACAWEVVRRAEIMRSFSLSTN 180
QY      180 LQESLRSKE 188
Db      181 LQKGLRSK 189
```

```
RESULT 12
Q6QNB6 HUMAN PRELIMINARY; PRT; 154 AA.
ID Q6QNB6 HUMAN
AC Q6QNB6
DT 05-JUL-2004, integrated into UniProtKB/TrEMBL.
DT 05-JUL-2004, sequence version 1.
DT 07-FEB-2006, entry version 11.
DE Interferon alpha A (Fragment).
GN Name=IFNA;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homnidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Behravan J., Ahmadpour H.;
RL Submitted (JAN-2004) to the EMBL/GenBank/DBJ databases.
CC -----
CC Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; AY532915; AAS92248.1; -; Genomic_DNA.
DR HSSP; P56828; 1B5L.
DR SMR; Q6QNB6; 1-154.
DR Ensembl; ENSG00000188379; Homo sapiens.
DR GO; GO:0005615; C:extracellular space; IEA.
DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
DR GO; GO:0006952; P:defense response; IEA.
DR GO; GO:0009615; P:response to virus; IEA.
DR InterPro; IPR000471; Interferon_abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR ProDom; PD000550; Interferon_abd; 1.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
KW Antiviral defense; Cytokine.
FT NON_TER 1 1
FT NON_TER 154 154
SQ SEQUENCE 154 AA; 17963 MW; 013C1B58B7E84A3 CRC64;
```

```
Query Match      81.9%; Score 786; DB 2; Length 154;
Best Local Similarity 98.7%; Pred. No. 2.1e-62;
Matches 152; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      25 DIPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFOKAETIPVLHEMIQ 84
Db      1 DIPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFOKAETIPVLHEMIQ 60
QY      85 QIFNLFSTKSSAAWDETLIDKFYTELYQQLNDLEACVIOGVGTETPLMKEDSILAVRK 144
Db      61 QIFNLFSTKSSAAWDETLIDKFYTELYQQLNDLEACVIOGVGTETPLMKEDSILAVRK 120
QY      145 YFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLST 178
Db      121 YFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLPT 154
```

```
RESULT 13
IFNA4 HUMAN STANDARD; PRT; 189 AA.
ID IFNA4 HUMAN
AC P05014; P13358;
DT 13-AUG-1987, integrated into UniProtKB/Swiss-Prot.
DT 10-MAY-2005, sequence version 2.
```

07-FEB-2006, entry version 61.
DE Interferon alpha-4 precursor (Interferon alpha-4B) (Interferon alpha-
DE M1) (Interferon alpha-76).
GN Name=IFNA4;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE, AND VARIANTS ALPHA-4B THR-74 AND VAL-137.
RX MEDLINE=86037205; PubMed=4057246;
RA Henco K., Brosius J., Fujisawa A., Fujisawa J., Haynes J.R.,
RA Hochstadt J., Kovacic T., Pasek M., Schamboeck A., Schmid J.,
RA Todokoro K., Maelchli M., Nagata S., Weismann C.;
RT "Structural relationship of human interferon alpha genes and
RT pseudogenes";
RL J. Mol. Biol. 185:227-260 (1985).
RN [2]
RP NUCLEOTIDE SEQUENCE.
RX MEDLINE=84307815; PubMed=6089830;
RA Linane A.W., Beilharz M.W., McNullen G.L., Macreadie I.G., Murphy M.,
RA Nisbet I.T., Novitski C.E., Woodrow G.C.;
RT "Nucleotide sequence and expression in E. coli of a human interferon-
RT alpha gene selected from a genomic library using synthetic
RT oligonucleotides";
RL Biochem. Int. 8:725-732 (1984).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT THR-74.
RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
RA Fahey J., Helton E., Kettelman M., Madan A., Rodriguez S., Sanchez A.,
RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
RA Butlerfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.;
RT "Generation and initial analysis of more than 15,000 full-length human
RT and mouse cDNA sequences";
RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903 (2002).
RN [4]
RP PROTEIN SEQUENCE OF 24-56.
RX MEDLINE=98087498; PubMed=9425112;
RA Nyman T.A., Toeloe H., Parkkinen J., Kalkkinen N.;
RT "Identification of nine interferon-alpha subtypes produced by Sendai
RT virus-induced human peripheral blood leucocytes";
RL Biochem. J. 329:295-302 (1998).
RN [5]
RP POLYMORPHISM.
RX MEDLINE=97474410; PubMed=9335434;
RA Hussain M., Gill D.S., Liao M.-J.;
RT "Both variant forms of interferon-alpha4 gene (IFNA4a and IFNA4b) are
RT present in the human population";
RL J. Interferon Cytokine Res. 17:559-566 (1997).
CC -I- FUNCTION: Produced by macrophages, IFN-alpha have antiviral
CC activities. Interferon stimulates the production of two enzymes: a
CC protein kinase and an oligoadenylate synthetase.
CC -I- SUBCELLULAR LOCATION: Secreted protein.
CC -I- POLYMORPHISM: Two forms exist; alpha-4a (shown here) and alpha-4b.
CC They seem to be equally abundant.
CC -I- SIMILARITY: Belongs to the alpha/beta interferon family.
CC -----
CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>

CC Distributed under the Creative Commons Attribution-NoDerivs License
CC -----
DR EMBL; X02955; CAA26701.1; -; Genomic_DNA.
DR EMBL; M27318; AAA52726.1; -; mRNA.
DR EMBL; BC074965; AAH74965.1; -; mRNA.
DR EMBL; BC074966; AAH74966.1; -; mRNA.
DR PIR; E23753; IVHU4B.
DR PIR; I52347; I52347.
DR HSSP; P01563; 1ITF.
DR SMR; P05014; 24-189.
DR Ensemble; ENSG00000147877; Homo sapiens.
DR HGNC; HGNC:5425; IFNA4.
DR MIM; 147564; gene.
DR GO; GO:0005132; F:interferon-alpha/beta receptor binding; TAS.
DR GO; GO:0009615; P:response to virus; TAS.
DR InterPro; IPR000471; Interferon abd.
DR PANTHER; PTHR11691; Interferon_abd; 1.
DR Pfam; PF00143; Interferon; 1.
DR PRINTS; PR00266; INTERFERONAB.
DR SMART; SM00076; IFabd; 1.
DR PROSITE; PS00252; INTERFERON A B D; 1.
KW Antiviral defense; Cytokine; Direct protein sequencing; Polymorphism;
KW Signal.
FT SIGNAL 1 23
FT CHAIN 24 189 Interferon alpha-4.
FT FT /FTid=PRO_0000016361.
FT FT By similarity.
FT FT DISULFID 24 122 By similarity.
FT FT DISULFID 52 162 By similarity.
FT FT VARIANT 74 74 A -> T (in alpha-4B; dbSNP:1062571).
FT FT /FTid=VAR_013002.
FT FT VARIANT 137 137 E -> V (in alpha-4B; dbSNP:3750480).
FT FT /FTid=VAR_013003.
SQ SEQUENCE 189 AA; 21808 MW; 828DF9C33ABC337F CRC64;

Query Match 81.4%; Score 781.5; DB 1; Length 189;
Best local similarity 81.5%; Pred. No. 6.9e-62;
Matches 154; Conservative 17; Mismatches 17; Indels 1; Gaps 1;

QY 1 MALTFALLVALVLVSKSSCSVGCDDLPTQTHSLGSRRTMLLAQMRRISLFSCLDRHDFG 60
Db 1 MALSFSLMAVLVLSYKSIKSLGCDLPQTHSLGNRRALLLLAQMGRIISHFSCLDHRHDFG 60
QY 61 FPQEEF-GNQFOKAEFTIPVLHEMIQOIFNLFGTKDSSAAWDETLDDKFTYELQQLNDLE 119
Db 61 FPBEEDGHQFOKQAISVLHEMIQOTFNLFTEDSSAAWESLLEKFTSTELQQLNDLE 120
QY 120 ACVIQGVGTETPLMKEDSILAVRKYFQRTITLYLKEKKYSPCAWEVRAEIMRSFSLSTN 179
Db 121 ACVIQEVGVEETPLMNEISILAVRKYFQRTITLYLKEKKYSPCAWEVRAEIMRSLSFSTN 180
QY 180 LQESLSRKE 188
Db 181 LQKRLRRKD 189

RESULT 14
Q5VV15 HUMAN PRELIMINARY; PRT; 189 AA.
ID Q5VV15;
AC Q5VV15;
DT 07-DEC-2004, integrated into UniProtKB/TrEMBL.
DT 07-DEC-2004, sequence version 1.
DT 21-FEB-2006, entry version 10.
DE Interferon, alpha 4.
GN Name=IFNA4; ORFNames=RP11-1P8.4-001;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Homidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE.
RA Pelan S.;
RL Submitted (MAY-2005) to the EMBL/GenBank/DBJ databases.

CC -1- SUBCELLULAR LOCATION: Secreted protein (By similarity).
 CC -----
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 DR EMBL: AL512606; CAH71188.1; -; Genomic_DNA.
 DR SMR; Q5VVI5; 24-189.
 DR Ensembl; ENSG00000147877; Homo sapiens.
 DR Linkhub; Q5VVI5; -
 DR GO; GO:0005615; C:extracellular space; IEA.
 DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
 DR GO; GO:0006952; P:defense response; IEA.
 DR GO; GO:000615; P:response to virus; IEA.
 DR InterPro; IPR000471; Interferon abd.
 DR PANTHER; PTHR11691; Interferon_abd; 1.
 DR Pfam; PF00143; Interferon; 1.
 DR PRINTS; PR00266; INTERFERONAB.
 DR ProDom; PD000550; Interferon_abd; 1.
 DR SMART; SM00076; IFabd; 1.
 DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
 DR Antiviral defense; Cytokine.
 KW Antiviral defense; Cytokine.
 SQ SEQUENCE 189 AA; 21808 MW; 828DF9C33ABC337F CRC64;

Query Match 81.4%; Score 781.5; DB 2; Length 189;
 Best Local Similarity 81.5%; Pred. No. 6.9e-62;
 Matches 154; Conservative 17; Mismatches 17; Indels 1; Gaps 1;
 QY 1 MALTFAALLVALLVLSCKSSGCVGCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
 DB 1 MALTFAALLVALLVLSCKSSGCVGCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
 QY 61 FPOEEF-GNQFQAKETIPVLHEMIOQIFNLFSTKSSAAWDETLDDKPYTELYQQLNDLE 119
 DB 61 FPOEEFDGNQFQAKAQAISVLHEMIOQIFNLFSTEDSSAAWQSLKEKSTELYQQLNDLE 120
 QY 120 ACVIOGVGTETPLMKEDSILA VRKYFORITLYLKEKYSPCAWEVVRAEIMRSLSLSTN 179
 DB 121 ACVIOGVGEETPLMNEDSILA VRKYFORITLYLKEKYSPCAWEVVRAEIMRSLSLSTN 180
 QY 180 LOESLSRKE 188
 DB 181 LQKRLRRKD 189

RESULT 15
 Q52LB8_HUMAN PRELIMINARY; PRT; 189 AA.
 ID Q52LB8_HUMAN
 AC Q52LB8;
 DT 24-MAY-2005, integrated into UniProtKB/TREMBL.
 DT 24-MAY-2005, sequence version 1.
 DT 21-FEB-2006, entry version 10.
 DE Interferon, alpha 13.
 GN Name=IFNA13;
 OS Homo sapiens (Human).
 OC Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Euarchontoglires; Primates; Catarrhini; Hominidae;
 OC Homo.
 OC NCBI_TaxID=9606;
 RN [1]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RX MEDLINE=22388257; PubMed=12477932; DOI=10.1073/pnas.242603899;
 RA Strausberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
 RA Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
 RA Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
 RA Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
 RA Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
 RA Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L., Scheetz T.E.,
 RA Brownstein M.J., Usdin T.B., Toshiyuki S., Carninci P., Prange C.,
 RA Raha S.S., Loquellano N.A., Peters G.J., Abramson R.D., Mullaly S.J.,
 RA Bosak S.A., McEwan P.J., McKernan K.J., Malek J.A., Gunaratne P.H.,
 RA Richards S., Worley K.C., Hale S., Garcia A.M., Gay L.J., Hulyk S.W.,
 RA Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,

RA Fahey J., Helton E., Kettelman M., Madan A., Rodrigues S., Sanchez A.,
 RA Whiting M., Madan A., Young A.C., Shevchenko Y., Bouffard G.G.,
 RA Blakesley R.W., Touchman J.W., Green E.D., Dickson M.C.,
 RA Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
 RA Butterfield Y.S.N., Krzywinski M.I., Skalska U., Smailus D.E.,
 RA Schnerch A., Schein J.E., Jones S.J.M., Marra M.A.,
 RT "Generation and initial analysis of more than 15,000 full-length human
 RT and mouse cDNA sequences.";
 RL Proc. Natl. Acad. Sci. U.S.A. 99:16899-16903(2002).
 RN [2]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RG NIH MGC Project;
 RL Submitted (APR-2005) to the EMBL/GenBank/DBJ databases.
 RN [3]
 RP NUCLEOTIDE SEQUENCE.
 RC TISSUE=Brain;
 RG NIH MGC Project;
 RL Submitted (JAN-2006) to the EMBL/GenBank/DBJ databases.
 CC -1- SUBCELLULAR LOCATION: Secreted protein (By similarity).
 CC -----
 CC Copyrighted by the UniProt Consortium, see <http://www.uniprot.org/terms>
 CC Distributed under the Creative Commons Attribution-NoDerivs License
 CC -----
 CC EMBL: BC093988; AAH93988.1; -; mRNA.
 DR EMBL; BC112002; AA112003.1; -; mRNA.
 DR SMR; Q52LB8; 24-189.
 DR Ensembl; ENSG00000120247; Homo sapiens.
 DR GO; GO:0005615; C:extracellular space; IEA.
 DR GO; GO:0005126; F:hematopoietin/interferon-class (D200-domain. . .; IEA.
 DR GO; GO:0006952; P:defense response; IEA.
 DR GO; GO:000615; P:response to virus; IEA.
 DR InterPro; IPR000471; Interferon abd.
 DR PANTHER; PTHR11691; Interferon_abd; 1.
 DR Pfam; PF00143; Interferon; 1.
 DR PRINTS; PR00266; INTERFERONAB.
 DR ProDom; PD000550; Interferon_abd; 1.
 DR SMART; SM00076; IFabd; 1.
 DR PROSITE; PS00252; INTERFERON_A_B_D; 1.
 DR Antiviral defense; Cytokine.
 KW Antiviral defense; Cytokine.
 SQ SEQUENCE 189 AA; 21697 MW; 442F8BB754D88398 CRC64;

Query Match 80.9%; Score 776.5; DB 2; Length 189;
 Best Local Similarity 82.5%; Pred. No. 1.9e-61;
 Matches 156; Conservative 10; Mismatches 22; Indels 1; Gaps 1;
 QY 1 MALTFAALLVALLVLSCKSSGCVGCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
 DB 1 MASPFAALLMALVLLVLSCKSSGCVGCDLPETHSLDNRRITMLLAQMSRISLSPSSCLMDRHDG 60
 QY 61 FPOEEF-GNQFQAKETIPVLHEMIOQIFNLFSTKSSAAWDETLDDKPYTELYQQLNDLE 119
 DB 61 FPOEEFDGNQFQAKAPAI SVLHEMIOQIFNLFSTKSSAAWDETLDDKPYTELYQQLNDLE 120
 QY 120 ACVIOGVGTETPLMKEDSILA VRKYFORITLYLKEKYSPCAWEVVRAEIMRSLSLSTN 179
 DB 121 ACVMQEEERVGETPLMNADSI LA VKYFRITLYLKEKYSPCAWEVVRAEIMRSLSLSTN 180
 QY 180 LOESLSRKE 188
 DB 181 LQERLRRKE 189

Search completed: October 14, 2006, 08:01:49
 Job time : 303 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: October 14, 2006, 08:02:07 ; Search time 53 Seconds
(without alignments)
310.486 Million cell updates/sec

Title: US-10-653-350-1

Perfect score: 960
Sequence: 1 MALTFALLVALVLVLSCKSSC.....EIMRSFSLSTNLQESLSRKE 188

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 650591 seqs, 87530628 residues

Total number of hits satisfying chosen parameters: 650591

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents AA:*
1: /EMC_Celerra_SIDS3/ptodata/2/1aa/5_COMB.pep:*
2: /EMC_Celerra_SIDS3/ptodata/2/1aa/6_COMB.pep:*
3: /EMC_Celerra_SIDS3/ptodata/2/1aa/7_COMB.pep:*
4: /EMC_Celerra_SIDS3/ptodata/2/1aa/H_COMB.pep:*
5: /EMC_Celerra_SIDS3/ptodata/2/1aa/PCTUS_COMB.pep:*
6: /EMC_Celerra_SIDS3/ptodata/2/1aa/RE_COMB.pep:*
7: /EMC_Celerra_SIDS3/ptodata/2/1aa/baCkfile1.pep:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	960	100.0	188	2	US-07-145-002B-26 Sequence 26, Appl
2	960	100.0	188	2	US-07-145-002B-35 Sequence 35, Appl
3	960	100.0	188	2	US-06-256-204C-26 Sequence 26, Appl
4	960	100.0	188	2	US-06-256-204C-35 Sequence 35, Appl
5	960	100.0	188	2	US-09-949-016-5966 Sequence 5966, Ap
6	960	100.0	188	2	US-09-915-873A-4 Sequence 4, Appli
7	960	100.0	205	2	US-09-949-016-8552 Sequence 8552, Ap
8	957	99.7	188	2	US-09-206-903A-7 Sequence 7, Appli
9	957	99.7	188	2	US-09-202-122-7 Sequence 7, Appli
10	957	99.7	188	2	US-09-206-935-9 Sequence 9, Appli
11	957	99.7	188	2	US-07-145-002B-2 Sequence 2, Appli
12	957	99.7	188	2	US-07-145-002B-17 Sequence 17, Appl
13	957	99.7	188	2	US-09-919-622A-7 Sequence 7, Appli
14	957	99.7	188	2	US-06-256-204C-2 Sequence 2, Appli
15	957	99.7	188	2	US-06-256-204C-17 Sequence 17, Appl
16	957	99.7	188	2	US-09-962-625-1 Sequence 1, Appli
17	957	99.7	188	2	US-09-599-413-3 Sequence 3, Appli
18	943	98.2	188	2	US-09-206-936-9 Sequence 9, Appli
19	937.5	97.7	189	1	US-08-026-758-4 Sequence 4, Appli
20	937	97.6	219	7	5310729-4 Patent No. 5310729
21	934.5	97.3	189	1	US-08-026-758-5 Sequence 5, Appli
22	929.5	96.8	189	7	5510472-7 Patent No. 5510472
23	895	93.2	195	7	5198345-17 Patent No. 5198345
24	851.5	88.7	188	1	US-08-249-671A-11 Sequence 11, Appli
25	851	88.6	165	1	US-08-024-330-1 Sequence 1, Appli
26	851	88.6	165	1	US-07-952-840-1 Sequence 1, Appli

27	851	88.6	165	1	US-08-356-021-1	Sequence 1, Appli
28	851	88.6	165	2	US-09-462-941-3	Sequence 3, Appli
29	851	88.6	165	2	US-06-256-204C-79	Sequence 79, Appl
30	851	88.6	165	2	US-09-915-873A-5	Sequence 5, Appli
31	851	88.6	165	5	PCT-US94-01729-1	Sequence 1, Appli
32	851	88.6	166	2	US-07-145-002B-53	Sequence 53, Appl
33	851	88.6	166	2	US-06-256-204C-53	Sequence 53, Appl
34	851	88.6	198	2	US-09-333-348B-11	Sequence 11, Appl
35	848	88.3	165	2	US-06-256-204C-71	Sequence 71, Appl
36	848	88.3	166	2	US-07-145-002B-45	Sequence 45, Appl
37	848	88.3	166	2	US-06-256-204C-45	Sequence 45, Appl
38	848	88.3	181	2	US-09-723-942-18	Sequence 18, Appl
39	848	88.3	181	2	US-09-723-775-18	Sequence 18, Appl
40	845	88.0	165	2	US-09-216-500-1	Sequence 1, Appli
41	845	88.0	165	2	US-09-730-464-1	Sequence 1, Appli
42	843	87.8	165	1	US-08-249-671A-5	Sequence 5, Appli
43	840.5	87.6	166	2	US-08-819-238A-1	Sequence 1, Appli
44	840.5	87.6	166	2	US-09-379-434-1	Sequence 1, Appli
45	835	87.0	165	7	5210029-3	Patent No. 5210029

ALIGNMENTS

RESULT 1
US-07-145-002B-26
; Sequence 26, Application US/07145002B
; Patent No. 6482613
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN
; TITLE OF INVENTION: LEUKOCYTE INTERFERONS
; FILE REFERENCE: 1803-0088-999
; CURRENT APPLICATION NUMBER: US/07/145, 002B
; CURRENT FILING DATE: 1989-01-19
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-07-145-002B-26

Query Match 100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MALTFALLVALVLVLSCKSSCGCDLPQTHSLGSRRTMLLAQMRRIISFSLCKDRHDFG	60
DB	1	MALTFALLVALVLVLSCKSSCGCDLPQTHSLGSRRTMLLAQMRRIISFSLCKDRHDFG	60
QY	61	FPQBEFGNQFQKATIPVLHEMIQIFNLFSKTDSSAAMDETLDDKFYTELYOQLNDLEA	120
DB	61	FPQBEFGNQFQKATIPVLHEMIQIFNLFSKTDSSAAMDETLDDKFYTELYOQLNDLEA	120
QY	121	CVIQGVGTETPLMKEDSILAVRKYFQRTILYLKEKKYSPCAWEVVRATIMRSFSLSTNL	180
DB	121	CVIQGVGTETPLMKEDSILAVRKYFQRTILYLKEKKYSPCAWEVVRATIMRSFSLSTNL	180
QY	181	QESLSRKE 188	
DB	181	QESLSRKE 188	

RESULT 2
US-07-145-002B-35
; Sequence 35, Application US/07145002B
; Patent No. 6482613
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN

```

; TITLE OF INVENTION: LEUKOCYTE INTERFERONS
; FILE REFERENCE: 1803-0088-999
; CURRENT APPLICATION NUMBER: US/07/145, 002B
; CURRENT FILING DATE: 1989-01-19
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-07-145-002B-35
```

```

Query Match          100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60
        |||||||
Db       1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60

QY      61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120
        |||||||
Db       61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120

QY      121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
        |||||||
Db       121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY      181 QESLSRKE 188
        |||||||
Db       181 QESLSRKE 188
```

```

RESULT 3
US-06-256-204C-26
; Sequence 26, Application US/06256204C
; Patent No. 6610830
; GENERAL INFORMATION:
; APPLICANT: Goedel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN
; TITLE OF INVENTION: LEUKOCYTE INTERFERONS
; FILE REFERENCE: 1803-0025-999
; CURRENT APPLICATION NUMBER: US/06/256, 204C
; CURRENT FILING DATE: 1981-04-21
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 26
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-06-256-204C-26
```

```

Query Match          100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60
        |||||||
Db       1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60

QY      61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120
        |||||||
Db       61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120

QY      121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
        |||||||
Db       121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY      181 QESLSRKE 188
        |||||||
Db       181 QESLSRKE 188
```

```

RESULT 4
US-06-256-204C-35
; Sequence 35, Application US/06256204C
; Patent No. 6610830
; GENERAL INFORMATION:
; APPLICANT: Goedel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN
; TITLE OF INVENTION: LEUKOCYTE INTERFERONS
; FILE REFERENCE: 1803-0025-999
; CURRENT APPLICATION NUMBER: US/06/256, 204C
; CURRENT FILING DATE: 1981-04-21
; NUMBER OF SEQ ID NOS: 85
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 35
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-06-256-204C-35
```

```

Query Match          100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60
        |||||||
Db       1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60

QY      61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120
        |||||||
Db       61 FPQEEFGNQFOKAETIPVLHMIQOIFNLFSTKSSAAMDETLLDKFYTELQQLNDLEA 120

QY      121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
        |||||||
Db       121 CVIQGVGTETPLMKEDSILA VRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY      181 QESLSRKE 188
        |||||||
Db       181 QESLSRKE 188
```

```

RESULT 5
US-09-949-016-5966
; Sequence 5966, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; TITLE OF INVENTION: WITH HUMAN DISEASE, METHODS OF DETECTION AND USES THEREOF
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949, 016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5966
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-5966
```

```

Query Match          100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRLSLSFSCDKDRHDFG 60
        |||||||
```

Db 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188
Db 181 QESLRSKE 188

RESULT 6
US-09-915-873A-4
; Sequence 4, Application US/09915873A
; Patent No. 6815184
; GENERAL INFORMATION:
; APPLICANT: Stomp, Anne-Marie
; APPLICANT: Dickey, Lynn
; APPLICANT: Gasdaska, John
; TITLE OF INVENTION: Expression of Biologically Active
; TITLE OF INVENTION: Polypeptides in Duckweed
; FILE REFERENCE: 40989/237225
; CURRENT APPLICATION NUMBER: US/09/915,873A
; CURRENT FILING DATE: 2001-07-26
; PRIOR APPLICATION NUMBER: US 60/293,330
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/221,705
; PRIOR FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-915-873A-4

Query Match 100.0%; Score 960; DB 2; Length 188;
Best Local Similarity 100.0%; Pred. No. 1.5e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
Db 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188
Db 181 QESLRSKE 188

RESULT 7
US-09-949-016-8552
; Sequence 8552, Application US/09949016
; Patent No. 6812339
; GENERAL INFORMATION:
; APPLICANT: VENTER, J. Craig et al.
; TITLE OF INVENTION: POLYMORPHISMS IN KNOWN GENES ASSOCIATED
; FILE REFERENCE: CL001307
; CURRENT APPLICATION NUMBER: US/09/949,016
; CURRENT FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/241,755

; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/237,768
; PRIOR FILING DATE: 2000-10-03
; PRIOR APPLICATION NUMBER: 60/231,498
; PRIOR FILING DATE: 2000-09-08
; NUMBER OF SEQ ID NOS: 207012
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8552
; LENGTH: 205
; TYPE: PRT
; ORGANISM: Human
US-09-949-016-8552

Query Match 100.0%; Score 960; DB 2; Length 205;
Best Local Similarity 100.0%; Pred. No. 1.7e-103;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
Db 18 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 77
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
Db 78 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 137
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 138 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 197
QY 181 QESLRSKE 188
Db 198 QESLRSKE 205

RESULT 8
US-09-206-903A-7
; Sequence 7, Application US/09206903A
; Patent No. 6200780
; GENERAL INFORMATION:
; APPLICANT: Chen, Jian
; APPLICANT: Godowski, Paul J.
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Dong-Xiao
; TITLE OF INVENTION: NOVEL TYPE I INTERFERONS
; FILE REFERENCE: P1224-2R1
; CURRENT APPLICATION NUMBER: US/09/206,903A
; CURRENT FILING DATE: 1998-12-07
; PRIOR APPLICATION NUMBER: US 60/106,463
; PRIOR FILING DATE: 1998-10-30
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 7
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-206-903A-7

Query Match 99.7%; Score 957; DB 2; Length 188;
Best Local Similarity 99.5%; Pred. No. 3.3e-103;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
Db 1 MALTFAALLVLLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRIISFSCDKDRHDFG 60
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFOKAETIPVLHEMIQIIFNLSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLRSKE 188

Db 181 QESLSRKE 188

RESULT 9

US-09-202-122-7
; Sequence 7, Application US/09202122
; Patent No. 6299869
; GENERAL INFORMATION:
; APPLICANT: Chen, Jian
; APPLICANT: Godowski, Paul
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Dong-Xiao
; TITLE OF INVENTION: HUMAN INTERFERON-EPSILON: A TYPE I INTERFERON
; FILE REFERENCE: P1224R2 (filed)
; CURRENT APPLICATION NUMBER: US/09/202,122
; CURRENT FILING DATE: 1999-03-04
; PRIOR APPLICATION NUMBER: PCT/US98/25672
; PRIOR FILING DATE: 1998-12-03
; NUMBER OF SEQ ID NOS: 12
; SEQ ID NO 7
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-202-122-7

Query Match 99.7%; Score 957; DB 2; Length 188;
Best Local Similarity 99.5%; Pred. No. 3.3e-103;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
Db 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 10
US-09-206-935-9

; Sequence 9, Application US/09206935
; Patent No. 6299877
; GENERAL INFORMATION:
; APPLICANT: Chen, Jian
; APPLICANT: Godowski, Paul
; APPLICANT: Wood, William I.
; APPLICANT: Zhang, Dong-Xiao
; TITLE OF INVENTION: NOVEL TYPE I INTERFERONS
; FILE REFERENCE: 11669.50US05
; CURRENT APPLICATION NUMBER: US/09/206,935
; CURRENT FILING DATE: 1998-12-07
; EARLIER APPLICATION NUMBER: 60/084,045
; EARLIER FILING DATE: 1998-05-04
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 9
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-206-935-9

Query Match 99.7%; Score 957; DB 2; Length 188;
Best Local Similarity 99.5%; Pred. No. 3.3e-103;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
Db 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 11
US-07-145-002B-2

; Sequence 2, Application US/07145002B
; Patent No. 6482613
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN
; FILE REFERENCE: 1803-0088-999
; CURRENT APPLICATION NUMBER: US/07/145,002B
; CURRENT FILING DATE: 1989-01-19
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-07-145-002B-2

Query Match 99.7%; Score 957; DB 2; Length 188;
Best Local Similarity 99.5%; Pred. No. 3.3e-103;
Matches 187; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
Db 1 MALTALLVALLVLSCKSSCSVGCGLPQTHSLGSRRTMLLAQMRRIISFSCICKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELQOINDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 12
US-07-145-002B-17

; Sequence 17, Application US/07145002B
; Patent No. 6482613
; GENERAL INFORMATION:
; APPLICANT: Goeddel, David V.
; APPLICANT: Pestka, Sidney
; TITLE OF INVENTION: MICROBIAL PRODUCTION OF MATURE HUMAN
; FILE REFERENCE: 1803-0088-999
; CURRENT APPLICATION NUMBER: US/07/145,002B
; CURRENT FILING DATE: 1989-01-19
; NUMBER OF SEQ ID NOS: 70
; SOFTWARE: FastSeq for Windows Version 3.0

Db	121	CVIOGVTEPINKEDSILAVRKYFORITLYIKKKYSPCAMEVVRAEIMRSFSLSTNL	180
Oy	181	QESLRSKE	188
Db	181	QESLRSKE	188

Search completed: October 14, 2006, 08:03:34
Job time : 54 secs


```

; Publication No. US20020088027A1
; GENERAL INFORMATION:
; APPLICANT: Stomp, Anne-Marie
; APPLICANT: Dickey, Lynn
; APPLICANT: Gasdaska, John
; TITLE OF INVENTION: Expression of Biologically Active
; FILE REFERENCE: 40989/237225
; CURRENT FILING DATE: 2001-07-26
; PRIOR FILING DATE: 2001-05-23
; PRIOR FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-915-873-4

```

```

Query Match      100.0%; Score 960; DB 3; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
    |||||||
DB 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
    |||||||
DB 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
    |||||||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY 181 QESLSRKE 188
    |||||||
DB 181 QESLSRKE 188

```

```

RESULT 3
US-10-087-325-2
; Sequence 2, Application US/10087325
; Publication No. US20020192682A1
; GENERAL INFORMATION:
; APPLICANT: Escary, Jean-Louis
; TITLE OF INVENTION: NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNalpha-2 GENE
; FILE REFERENCE: 021349/0010
; CURRENT FILING DATE: 2002-03-01
; PRIOR FILING DATE: 2001-03-01
; PRIOR FILING DATE: 2001-03-01
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn version 3.1.1
; SEQ ID NO 2
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-087-325-2

```

```

Query Match      100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
    |||||||
DB 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
    |||||||

```

```

DB 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
    |||||||
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
    |||||||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY 181 QESLSRKE 188
    |||||||
DB 181 QESLSRKE 188

```

```

RESULT 4
US-10-411-037-4
; Sequence 4, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bove, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR FILING DATE: 2001-10-10
; PRIOR FILING DATE: 2001-10-19
; PRIOR FILING DATE: 2002-06-07
; PRIOR FILING DATE: 2002-06-25
; PRIOR FILING DATE: 2002-06-25
; PRIOR FILING DATE: 2002-07-17
; PRIOR FILING DATE: 2002-08-16
; PRIOR FILING DATE: 2002-08-16
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-10-411-037-4

```

```

Query Match      100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
    |||||||
DB 1 MALTFAALLVALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
    |||||||
DB 61 FPQEEFGNQFQKAETIPVLHEMIQIIFNLSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
    |||||||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180

QY 181 QESLSRKE 188
    |||||||
DB 181 QESLSRKE 188

```

```

RESULT 5
US-10-411-026-4

```



```

; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-049-4

Query Match          100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
    |||||||
Db 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
    |||||||
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
    |||||||
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180

QY 181 QESLRSKE 188
    |||||||
Db 181 QESLRSKE 188
```

RESULT 8

US-10-410-930-4

; Sequence 4, Application US/10410930

; Publication No. US20040115168A1

; GENERAL INFORMATION:

; APPLICANT: Neose Technologies, Inc.

; APPLICANT: Defrees, Shawn

; APPLICANT: Zopf, David

; APPLICANT: Bayer, Robert

; APPLICANT: Hakes, David

; APPLICANT: Chen, Xi

; APPLICANT: Bowe, Caryn

; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

; TITLE OF INVENTION: BETA

; FILE REFERENCE: 040853-01-5056

; CURRENT APPLICATION NUMBER: US/10/410,930

; CURRENT FILING DATE: 2003-04-09

; PRIOR APPLICATION NUMBER: US 60/328,523

; PRIOR FILING DATE: 2001-10-10

; PRIOR APPLICATION NUMBER: US 60/344,692

; PRIOR FILING DATE: 2001-10-19

; PRIOR APPLICATION NUMBER: US 60/387,292

; PRIOR FILING DATE: 2002-06-07

; PRIOR APPLICATION NUMBER: US 60/391,777

; PRIOR FILING DATE: 2002-06-25

; PRIOR APPLICATION NUMBER: US 60/396,594

; PRIOR FILING DATE: 2002-07-17

; PRIOR APPLICATION NUMBER: US 60/404,249

; PRIOR FILING DATE: 2002-08-16

; PRIOR APPLICATION NUMBER: US 60/407,527

; PRIOR FILING DATE: 2002-08-28

; NUMBER OF SEQ ID NOS: 75

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 4

; LENGTH: 188

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-410-930-4

```

Query Match          100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
    |||||||
Db 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
    |||||||
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
    |||||||
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180

QY 181 QESLRSKE 188
    |||||||
Db 181 QESLRSKE 188
```

RESULT 9

US-10-410-997-4

; Sequence 4, Application US/10410997

; Publication No. US20040126838A1

; GENERAL INFORMATION:

; APPLICANT: Neose Technologies, Inc.

; APPLICANT: Defrees, Shawn

; APPLICANT: Zopf, David

; APPLICANT: Bayer, Robert

; APPLICANT: Hakes, David

; APPLICANT: Chen, Xi

; APPLICANT: Bowe, Caryn

; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF

; TITLE OF INVENTION: FSH

; FILE REFERENCE: 040853-01-5059

; CURRENT APPLICATION NUMBER: US/10/410,997

; CURRENT FILING DATE: 2003-04-09

; PRIOR APPLICATION NUMBER: US 60/328,523

; PRIOR FILING DATE: 2001-10-10

; PRIOR APPLICATION NUMBER: US 60/344,692

; PRIOR FILING DATE: 2001-10-19

; PRIOR APPLICATION NUMBER: US 60/387,292

; PRIOR FILING DATE: 2002-06-07

; PRIOR APPLICATION NUMBER: US 60/391,777

; PRIOR FILING DATE: 2002-06-25

; PRIOR APPLICATION NUMBER: US 60/396,594

; PRIOR FILING DATE: 2002-07-17

; PRIOR APPLICATION NUMBER: US 60/404,249

; PRIOR FILING DATE: 2002-08-16

; PRIOR APPLICATION NUMBER: US 60/407,527

; PRIOR FILING DATE: 2002-08-28

; NUMBER OF SEQ ID NOS: 75

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 4

; LENGTH: 188

; TYPE: PRT

; ORGANISM: Homo sapiens

US-10-410-997-4

```

Query Match          100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
    |||||||
Db 1 MALTFAALLVALLVLSCKSSCSVGCDDLPTHTSLGSRRTMLLAQMRISLFSCLKDRHDFG 60

QY 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
    |||||||
Db 61 FPQEEFGNQFQKAETIPVLHEMIQOIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120

QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
    |||||||
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL 180
```

QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 10
US-10-411-012-4

; Sequence 4, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONGUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT FILING DATE: US/10/411,012
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-411-012-4

Query Match 100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALLVLLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALLVLLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQIFNLFSFKDSSAAWDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQIFNLFSFKDSSAAWDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 11

US-10-287-994-4
; Sequence 4, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David

; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi

; TITLE OF INVENTION: REMODELING AND GLYCOCONGUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-287-994-4

Query Match 100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFAALLVLLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
Db 1 MALTFAALLVLLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
QY 61 FPQEEFGNQFQKAETIPVLHEMIQIFNLFSFKDSSAAWDETLDDKFTYELYYQQLNDLEA 120
Db 61 FPQEEFGNQFQKAETIPVLHEMIQIFNLFSFKDSSAAWDETLDDKFTYELYYQQLNDLEA 120
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
Db 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
QY 181 QESLSRKE 188
Db 181 QESLSRKE 188

RESULT 12

US-10-410-913-4
; Sequence 4, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONGUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292

;; PRIOR FILING DATE: 2002-06-07
;; PRIOR APPLICATION NUMBER: US 60/391,777
;; PRIOR FILING DATE: 2002-06-25
;; PRIOR APPLICATION NUMBER: US 60/396,594
;; PRIOR FILING DATE: 2002-07-17
;; PRIOR APPLICATION NUMBER: US 60/404,249
;; PRIOR FILING DATE: 2002-08-16
;; PRIOR APPLICATION NUMBER: US 60/407,527
;; PRIOR FILING DATE: 2002-08-28
;; NUMBER OF SEQ ID NOS: 75
;; SOFTWARE: PatentIn version 3.2
;; SEQ ID NO 4
;; LENGTH: 188
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-410-913-4

Query Match 100.0%; Score 960; DB 4; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
|||
DB 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
DB 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||
QY 181 QESLSRKE 188
|||
DB 181 QESLSRKE 188
|||

RESULT 13
US-10-276-642-12

;; Sequence 12, Application US/10276642
;; Publication No. US20040235156A1
;; GENERAL INFORMATION:
;; APPLICANT: Ralph, Stephen John
;; TITLE OF INVENTION: IMMUNE POTENTIATING COMPOSITIONS
;; FILE REFERENCE: DAVI200.001APC
;; CURRENT APPLICATION NUMBER: US/10/276,642
;; CURRENT FILING DATE: 2002-11-15
;; PRIOR APPLICATION NUMBER: PCT/AU01/00565
;; PRIOR FILING DATE: 2001-05-17
;; PRIOR APPLICATION NUMBER: PQ 7553
;; PRIOR FILING DATE: 2000-05-17
;; NUMBER OF SEQ ID NOS: 20
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 12
;; LENGTH: 188
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-276-642-12

Query Match 100.0%; Score 960; DB 5; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
|||
DB 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
DB 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||

|||||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||
QY 181 QESLSRKE 188
|||
DB 181 QESLSRKE 188
|||

RESULT 14
US-10-794-615-4

;; Sequence 4, Application US/10794615
;; Publication No. US20040261148A1
;; GENERAL INFORMATION:
;; APPLICANT: Dickey, Lynn
;; APPLICANT: Gasdaska, John
;; APPLICANT: Cox, Kevin
;; TITLE OF INVENTION: Expression of Biologically Active
;; FILE REFERENCE: 40989/267934
;; CURRENT APPLICATION NUMBER: US/10/794,615
;; CURRENT FILING DATE: 2004-03-05
;; PRIOR APPLICATION NUMBER: US/10/675,011
;; PRIOR FILING DATE: 2003-09-30
;; PRIOR APPLICATION NUMBER: US 09/915,873
;; PRIOR FILING DATE: 2001-07-26
;; PRIOR APPLICATION NUMBER: US 60/293,330
;; PRIOR FILING DATE: 2001-05-23
;; PRIOR APPLICATION NUMBER: US 60/221,705
;; PRIOR FILING DATE: 2000-07-31
;; NUMBER OF SEQ ID NOS: 16
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 4
;; LENGTH: 188
;; TYPE: PRT
;; ORGANISM: Homo sapiens
US-10-794-615-4

Query Match 100.0%; Score 960; DB 5; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
|||
DB 1 MALTFALLVALLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRISLFSCLKDRHDFG 60
61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
QY 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
DB 61 FPQEEFGNQFOKAETIPVLHEMIQIENLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
|||
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||
DB 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
|||
QY 181 QESLSRKE 188
|||
DB 181 QESLSRKE 188
|||

RESULT 15
US-10-653-350-1

;; Sequence 1, Application US/10653350
;; Publication No. US20050019871A1
;; GENERAL INFORMATION:
;; APPLICANT: Lee, Eun Jung
;; APPLICANT: Park, Hyung Ki
;; APPLICANT: Park, Ji Sook
;; APPLICANT: Kim, Yeon Hyang
;; APPLICANT: Lee, Hyune Soo
;; APPLICANT: Koh, Hyung Kon
;; APPLICANT: Oh, Myung Suk
;; TITLE OF INVENTION: GLYCOSYLATED HUMAN INTERFERON ALPHA
;; FILE REFERENCE: A35967 073226.0119

;; CURRENT APPLICATION NUMBER: US/10/653,350
;; CURRENT FILING DATE: 2003-09-02
;; PRIOR APPLICATION NUMBER: KR 10-2002-0052365
;; PRIOR FILING DATE: 2002-08-31
;; NUMBER OF SEQ ID NOS: 19
;; SOFTWARE: FastSeq for Windows Version 4.0
;; SEQ ID NO 1
;; LENGTH: 188
;; TYPE: PRT
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Human interferon alpha isoform
;; FEATURE:
;; NAME/KEY: SIGNAL
;; LOCATION: (1)...(23)
;; OTHER INFORMATION: Propeptide
US-10-653-350-1

Query Match 100.0%; Score 960; DB 5; Length 188;
Best Local Similarity 100.0%; Pred. No. 9.8e-94;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MALTFALVALVLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG	60
DB	1	MALTFALVALVLVLSCKSSCSVGCDDLPOTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG	60
QY	61	FPOEFGNQFOKAETIPVLHEMIQOIFNLFSTKXSSAAWDETLDDKFYTELYQQLNDLEA	120
DB	61	FPOEFGNQFOKAETIPVLHEMIQOIFNLFSTKXSSAAWDETLDDKFYTELYQQLNDLEA	120
QY	121	CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL	180
DB	121	CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRAEIMRSFSLSTNL	180
QY	181	QESLRSKE	188
DB	181	QESLRSKE	188

Search completed: October 14, 2006, 08:06:40
Job time : 180 secs

GenCore version 5.1.9
Copyright (c) 1993 - 2006 Bioceleration Ltd.

OM protein - protein search, using sw model

Run on: October 14, 2006, 08:03:47 ; Search time 39 Seconds
(without alignments)
382.774 Million cell updates/sec

Title: US-10-653-350-1
Perfect score: 960
Sequence: 1 MALTFAVLVALVLSCSKSSC.....EIMRFSLSSTNLQESLSRKE 188

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 295242 seqs, 79405279 residues

Total number of hits satisfying chosen parameters: 295242

Minimum DB seq length: 0
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications AA New:
1: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US09_NEW_PUB.pep:*
2: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US06_NEW_PUB.pep:*
3: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US07_NEW_PUB.pep:*
4: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US08_NEW_PUB.pep:*
5: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/PCT_NEW_PUB.pep:*
6: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US10_NEW_PUB.pep:*
7: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US11_NEW_PUB.pep:*
8: /EMC_Celerra_SIDS3/ptodata/1/pubpaa/US60_NEW_PUB.pep:*

** Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	960	100.0	188	6	US-10-675-011-4	Sequence 4, Appli
2	960	100.0	188	7	US-11-183-218-4	Sequence 4, Appli
3	960	100.0	773	7	US-11-429-276-403	Sequence 403, App
4	867	90.3	201	7	US-11-036-257-79	Sequence 79, Appl
5	867	90.3	231	7	US-11-036-257-85	Sequence 85, Appl
6	863	89.9	209	7	US-11-036-257-65	Sequence 65, Appl
7	860.5	89.6	196	7	US-11-036-257-83	Sequence 83, Appl
8	860.5	89.6	206	7	US-11-036-257-81	Sequence 81, Appl
9	859	89.5	192	6	US-10-568-332-14	Sequence 14, Appl
10	856	89.2	774	7	US-11-429-276-352	Sequence 352, App
11	855.5	89.1	226	7	US-11-036-257-87	Sequence 87, Appl
12	855.5	89.1	769	7	US-11-429-276-386	Sequence 386, App
13	855.5	89.1	769	7	US-11-429-276-407	Sequence 407, App
14	853.5	88.9	774	7	US-11-429-276-402	Sequence 402, App
15	853.5	88.9	774	7	US-11-429-276-1300	Sequence 1300, Ap
16	851	88.6	165	6	US-10-675-011-5	Sequence 5, Appli
17	851	88.6	165	7	US-11-370-555-30	Sequence 30, Appl
18	851	88.6	165	7	US-11-330-917-1	Sequence 1, Appli
19	851	88.6	165	7	US-11-363-637-30	Sequence 30, Appl
20	851	88.6	165	7	US-11-429-276-568	Sequence 568, App
21	851	88.6	165	7	US-11-429-276-602	Sequence 602, App
22	851	88.6	165	7	US-11-429-276-613	Sequence 613, App
23	851	88.6	165	7	US-11-429-276-618	Sequence 618, App
24	851	88.6	165	7	US-11-429-276-619	Sequence 619, App
25	851	88.6	165	7	US-11-429-276-623	Sequence 623, App

26	851	88.6	165	7	US-11-429-276-1302	Sequence 1302, Ap
27	851	88.6	165	7	US-11-351-163-1	Sequence 1, Appli
28	851	88.6	166	6	US-10-933-854-12	Sequence 12, Appl
29	851	88.6	166	7	US-11-351-163-1357	Sequence 1357, Ap
30	851	88.6	539	7	US-11-244-3498-37	Sequence 37, Appl
31	851	88.6	835	7	US-11-429-276-397	Sequence 397, App
32	849	88.4	165	7	US-11-330-917-84	Sequence 84, Appl
33	849	88.4	165	7	US-11-330-917-103	Sequence 103, App
34	849	88.4	165	7	US-11-330-917-109	Sequence 109, App
35	849	88.4	165	7	US-11-351-163-84	Sequence 84, Appl
36	849	88.4	165	7	US-11-351-163-103	Sequence 103, App
37	849	88.4	165	7	US-11-351-163-109	Sequence 109, App
38	848	88.3	165	7	US-11-330-917-7	Sequence 7, Appli
39	848	88.3	165	7	US-11-330-917-10	Sequence 10, Appl
40	848	88.3	165	7	US-11-330-917-20	Sequence 20, Appl
41	848	88.3	165	7	US-11-330-917-22	Sequence 22, Appl
42	848	88.3	165	7	US-11-330-917-54	Sequence 54, Appl
43	848	88.3	165	7	US-11-330-917-72	Sequence 72, Appl
44	848	88.3	165	7	US-11-330-917-76	Sequence 76, Appl
45	848	88.3	165	7	US-11-330-917-87	Sequence 87, Appl

ALIGNMENTS

RESULT 1
US-10-675-011-4
; Sequence 4, Application US/10675011
; Publication No. US20060195946A1
; GENERAL INFORMATION:
; APPLICANT: Dickey, Lynn
; APPLICANT: Gasdaska, John
; APPLICANT: Cox, Kevin
; TITLE OF INVENTION: Expression of Biologically Active
; FILE REFERENCE: 40989/267934
; CURRENT APPLICATION NUMBER: US/10/675,011
; CURRENT FILING DATE: 2003-09-30
; PRIOR APPLICATION NUMBER: US 09/915,873
; PRIOR FILING DATE: 2001-07-26
; PRIOR APPLICATION NUMBER: US 60/293,330
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/221,705
; PRIOR FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-675-011-4

Query Match 100.0%; Score 960; DB 6; Length 188;
Best Local Similarity 100.0%; Pred. No. 8.7e-86;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1	MALTFAVLVALVLSCSKSSVGC	DLPQTHSLGSRRTMLLAQMRRISL	FSCIKDRHDFG	60	
Db	1	MALTFAVLVALVLSCSKSSVGC	DLPQTHSLGSRRTMLLAQMRRISL	FSCIKDRHDFG	60	
QY	61	FPOEEFGNOFOKAETIPVLH	EMIQIIFNLSTKSSAAMD	ETLLDKFYTEL	QOQLNDLEA 120	
Db	61	FPOEEFGNOFOKAETIPVLH	EMIQIIFNLSTKSSAAMD	ETLLDKFYTEL	QOQLNDLEA 120	
QY	121	CVIQGVTEPPLMKEDSILA	VRKYFORITLLYLKEK	YSPCAMEVVR	AEIMRFSLS	TNL 180
Db	121	CVIQGVTEPPLMKEDSILA	VRKYFORITLLYLKEK	YSPCAMEVVR	AEIMRFSLS	TNL 180
QY	181	QESLSRKE	188			
Db	181	QESLSRKE	188			

```
RESULT 2
US-11-183-218-4
; Sequence 4, Application US/11183218
; Publication No. US20060088906A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryne
; TITLE OF INVENTION: ERYTHROPOIETIN: REMODELING AND
; TITLE OF INVENTION: GLYCOCONJUGATION OF ERYTHROPOIETIN
; FILE REFERENCE: 040853-01-5083-US02
; CURRENT APPLICATION NUMBER: US/11/183,218
; CURRENT FILING DATE: 2005-07-15
; PRIOR APPLICATION NUMBER: US 10/410,945
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: PCT/US02/32263
; PRIOR FILING DATE: 2002-10-09
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-11-19
; PRIOR APPLICATION NUMBER: US 60/334,301
; PRIOR FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: US 60/334,233
; PRIOR FILING DATE: 2001-11-28
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 188
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-183-218-4

Query Match          100.0%; Score 960; DB 7; Length 188;
Best Local Similarity 100.0%; Pred. No. 8.7e-86;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60
      |||
DB      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60

QY      61 FPQEEFGNQFOKAEITPVLHEMIQIIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
      |||
DB      61 FPQEEFGNQFOKAEITPVLHEMIQIIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120

QY      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTNL 180
      |||
DB      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTNL 180

QY      181 QESLRSKE 188
      |||
DB      181 QESLRSKE 188

RESULT 3
US-11-429-276-403
; Sequence 403, Application US/11429276
; Publication No. US20060194735A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
```

```
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564
; CURRENT APPLICATION NUMBER: US/11/429,276
; CURRENT FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; PRIOR FILING DATE: 2002-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 403
; LENGTH: 773
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-429-276-403
```

```
Query Match          100.0%; Score 960; DB 7; Length 773;
Best Local Similarity 100.0%; Pred. No. 5e-85;
Matches 188; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60
      |||
DB      1 MALTFALLVALLVLSCKSSCSVGCDDLPTHSLGSRRTMLLAQMRRLSFSCLKDRHDFG 60

QY      61 FPQEEFGNQFOKAEITPVLHEMIQIIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120
      |||
DB      61 FPQEEFGNQFOKAEITPVLHEMIQIIFNLFSTKSSAAWDETLDDKFTYELYYQQLNDLEA 120

QY      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTNL 180
      |||
DB      121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVVRRAEIMRSFSLSTNL 180

QY      181 QESLRSKE 188
      |||
DB      181 QESLRSKE 188

RESULT 4
US-11-036-257-79
; Sequence 79, Application US/11036257
; Publication No. US20060148680A1
; GENERAL INFORMATION:
; APPLICANT: KIELISZEWSKI, MARCIA
; APPLICANT: XU, JIANFENG
; APPLICANT: KOPCHICK, JOHN J.
; APPLICANT: OKADA, SHIGERU
; TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
; TITLE OF INVENTION: THEIR USE
; FILE REFERENCE: 27211/04081
; CURRENT APPLICATION NUMBER: US/11/036,257
; CURRENT FILING DATE: 2005-01-14
; PRIOR APPLICATION NUMBER: 60/602,562
; PRIOR FILING DATE: 2004-08-18
; PRIOR APPLICATION NUMBER: 60/582,027
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
```

; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 79
; LENGTH: 201
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-79

Query Match 90.3%; Score 867; DB 7; Length 201;
Best Local Similarity 91.0%; Pred. No. 1e-76;
Matches 171; Conservative 4; Mismatches 13; Indels 0; Gaps 0;

QY 1 MALTFAALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
| | | | | : | | | | | : | | | | | | | | | | | | | | | | | | | | |
DB 4 MASLFATFLVLSLSLAQTTRACDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 63
QY 61 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 64 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 123
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 124 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 183
QY 181 QESLSRKE 188
| | | | | | | |
DB 184 QESLSRKE 191

RESULT 5
US-11-036-257-85
; Sequence 85, Application US/11036257
; Publication No. US20060148680A1
; GENERAL INFORMATION:
; APPLICANT: KIELISZEWSKI, MARCIA
; APPLICANT: XU, JIANFENG
; APPLICANT: KOPCHICK, JOHN J.
; APPLICANT: OKADA, SHIGERU
; TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
; TITLE OF INVENTION: THEIR USE
; FILE REFERENCE: 27211/04081
; CURRENT APPLICATION NUMBER: US/11/036,257
; CURRENT FILING DATE: 2005-01-14
; PRIOR APPLICATION NUMBER: 60/602,562
; PRIOR FILING DATE: 2004-08-18
; PRIOR APPLICATION NUMBER: 60/582,027
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 85
; LENGTH: 231
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-85

Query Match 90.3%; Score 867; DB 7; Length 231;
Best Local Similarity 91.0%; Pred. No. 1.2e-76;
Matches 171; Conservative 4; Mismatches 13; Indels 0; Gaps 0;

QY 1 MALTFAALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
| | | | | : | | | | | : | | | | | | | | | | | | | | | | | | | | |
DB 4 MASLFATFLVLSLSLAQTTRACDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 63
QY 61 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120

DB 64 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 123
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 124 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 183
QY 181 QESLSRKE 188
| | | | | | | |
DB 184 QESLSRKE 191

RESULT 6
US-11-036-257-65
; Sequence 65, Application US/11036257
; Publication No. US20060148680A1
; GENERAL INFORMATION:
; APPLICANT: KIELISZEWSKI, MARCIA
; APPLICANT: XU, JIANFENG
; APPLICANT: KOPCHICK, JOHN J.
; APPLICANT: OKADA, SHIGERU
; TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
; TITLE OF INVENTION: THEIR USE
; FILE REFERENCE: 27211/04081
; CURRENT APPLICATION NUMBER: US/11/036,257
; CURRENT FILING DATE: 2005-01-14
; PRIOR APPLICATION NUMBER: 60/602,562
; PRIOR FILING DATE: 2004-08-18
; PRIOR APPLICATION NUMBER: 60/582,027
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 65
; LENGTH: 209
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-65

Query Match 89.9%; Score 863; DB 7; Length 209;
Best Local Similarity 92.0%; Pred. No. 2.6e-76;
Matches 173; Conservative 1; Mismatches 12; Indels 2; Gaps 1;

QY 1 MALTFAALLVLSCKSSCVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 60
| | | | | : | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 4 MASLFATF--LVVLVLSLSLAQTTCCLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFG 61
QY 61 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 120
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 62 FPQEEFGNQFQKAEITIPVLHEMIQQIFNLFSTKSSAAMDETLDDKFTYELYYQQLNDLEA 121
QY 121 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 180
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
DB 122 CVIQGVGTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNL 181
QY 181 QESLSRKE 188
| | | | | | | |
DB 182 QESLSRKE 189

RESULT 7
US-11-036-257-83
; Sequence 83, Application US/11036257
; Publication No. US20060148680A1
; GENERAL INFORMATION:
; APPLICANT: KIELISZEWSKI, MARCIA
; APPLICANT: XU, JIANFENG
; APPLICANT: KOPCHICK, JOHN J.
; APPLICANT: OKADA, SHIGERU

TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
; TITLE OF INVENTION: THEIR USE
; FILE REFERENCE: 27211/04081
; CURRENT APPLICATION NUMBER: US/11/036,257
; PRIOR FILING DATE: 2005-01-14
; PRIOR APPLICATION NUMBER: 60/602,562
; PRIOR FILING DATE: 2004-08-18
; PRIOR APPLICATION NUMBER: 60/582,027
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 83
; LENGTH: 196
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-83

Query Match 89.6%; Score 860.5; DB 7; Length 196;
Best Local Similarity 89.6%; Pred. No. 4.2e-76;
Matches 173; Conservative 3; Mismatches 12; Indels 5; Gaps 1;

OY 1 MALTPALLVALLVLSCKSSCSVG-----CDLPQTHSLGSRRTMLLAQMRRISLFSCLKD 55
||| :||| :||| |||||
Db 4 MASLFATFLVVLVLSLSPSPSPSPCDLPQTHSLGSRRTMLLAQMRRISLFSCLKD 63
OY 56 RHDGFPQEEFGNQFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQL 115
||||| :||| :||| |||||
Db 64 RHDGFPQEEFGNQFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQL 123
OY 116 NDLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFS 175
||||| :||| :||| |||||
Db 124 NDLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFS 183
OY 176 LSTNLQESLSRKE 188
||||| :||| :||| |||||
Db 184 LSTNLQESLSRKE 196

RESULT 8

US-11-036-257-81
; Sequence 81, Application US/11036257
; Publication No. US20060148680A1
; GENERAL INFORMATION:
; APPLICANT: KIELISZEWSKI, MARCIA
; APPLICANT: XU, JIANFENG
; APPLICANT: KOPCHICK, JOHN J.
; APPLICANT: OKADA, SHIGERU
; TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
; TITLE OF INVENTION: THEIR USE
; FILE REFERENCE: 27211/04081
; CURRENT APPLICATION NUMBER: US/11/036,257
; CURRENT FILING DATE: 2005-01-14
; PRIOR APPLICATION NUMBER: 60/602,562
; PRIOR FILING DATE: 2004-08-18
; PRIOR APPLICATION NUMBER: 60/582,027
; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 81
; LENGTH: 206
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-81

Query Match 89.6%; Score 860.5; DB 7; Length 206;
Best Local Similarity 89.6%; Pred. No. 4.5e-76;
Matches 173; Conservative 3; Mismatches 12; Indels 5; Gaps 1;

OY 1 MALTPALLVALLVLSCKSSCSVG-----CDLPQTHSLGSRRTMLLAQMRRISLFSCLKD 55
||| :||| :||| |||||
Db 4 MASLFATFLVVLVLSLSPSPSPSPCDLPQTHSLGSRRTMLLAQMRRISLFSCLKD 63
OY 56 RHDGFPQEEFGNQFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQL 115
||||| :||| :||| |||||
Db 64 RHDGFPQEEFGNQFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQL 123
OY 116 NDLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFS 175
||||| :||| :||| |||||
Db 124 NDLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFS 183
OY 176 LSTNLQESLSRKE 188
||||| :||| :||| |||||
Db 184 LSTNLQESLSRKE 196

RESULT 9

US-10-568-332-14
; Sequence 14, Application US/10568332
; Publication No. US20060173167A1
; GENERAL INFORMATION:
; APPLICANT: Stempfer, Gunter
; APPLICANT: Alliger, Peter
; APPLICANT: Palma, Norbert
; TITLE OF INVENTION: Process for the purification of recombinant polypeptides
; FILE REFERENCE: BP/G-33315A ENG 61310.US
; CURRENT APPLICATION NUMBER: US/10/568,332
; CURRENT FILING DATE: 2006-02-13
; PRIOR APPLICATION NUMBER: PCT/EP2004/009055
; PRIOR FILING DATE: 2004-08-12
; PRIOR APPLICATION NUMBER: US 60/494,915
; PRIOR FILING DATE: 2003-08-13
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 14
; LENGTH: 192
; TYPE: PRT
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic Construct
US-10-568-332-14

Query Match 89.5%; Score 859; DB 6; Length 192;
Best Local Similarity 92.8%; Pred. No. 5.8e-76;
Matches 168; Conservative 3; Mismatches 10; Indels 0; Gaps 0;

OY 8 LVALLVLSCKSSCSVGCDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFGPOEEFG 67
||| :||| :||| |||||
Db 12 LVMATVIGLAPAVAFACDLPQTHSLGSRRTMLLAQMRRISLFSCLKDRHDFGPOEEFG 71
OY 68 NOFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQLNDLEACVIGYG 127
||||| :||| :||| |||||
Db 72 NOFOKAETIPVLHMIQIIFNLSTKSSAAMDETLDDKFTELYQQLNDLEACVIGYG 131
OY 128 VTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFSLSTNLQESLSRKE 187
||||| :||| :||| |||||
Db 132 VTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAWEVRAEIMRSFSLSTNLQESLSRKE 191
OY 188 E 188
|
Db 192 E 192

RESULT 10

US-11-429-276-352
; Sequence 352, Application US/11429276
; Publication No. US20060194735A1

```

; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564
; CURRENT APPLICATION NUMBER: US/11/429,276
; CURRENT FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; PRIOR FILING DATE: 2002-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 352
; LENGTH: 774
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-429-276-352

```

Query Match	89.2%	Score 856	DB 7	Length 774
Best Local Similarity	90.9%	Pred. No. 6.3e-75		
Matches 169	Conservative 4	Mismatches 13	Indels 0	Gaps 0

QY	3	LTFALLVALVLVLSCKSSCSVGCDFPQTHSLGSRRTMLLAQMRRIISFLSCLKDRHDFGFP	62
Db	4	VSFISLFLFSSAYSRSRLDKRCDFPQTHSLGSRRTMLLAQMRRIISFLSCLKDRHDFGFP	63
QY	63	QEEFGNQFOKAETIPVLHEMIQOIENLFTKSSAAMDETLDDKFTYELYYQQLNDLEACV	122
Db	64	QEEFGNQFOKAETIPVLHEMIQOIFNLFTKSSAAMDETLDDKFTYELYYQQLNDLEACV	123
QY	123	IQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAETMRSFSLSTNLOE	182
Db	124	IQGVGTETPLMKEDSILAVRKYFORITLYLKEKYSPCAMEVVRRAETMRSFSLSTNLOE	183
QY	183	SLRSKE	188
Db	184	SLRSKE	189


```

RESULT 11
US-11-036-257-87
: Sequence 87, Application US/11036257
: Publication No. US20060148680A1
: GENERAL INFORMATION:
: APPLICANT: KIELISZEWSKI, MARCIA
: APPLICANT: XU, JIANFENG
: APPLICANT: KOPCHICK, JOHN J.
: APPLICANT: OKADA, SHIGERU
: TITLE OF INVENTION: GLYCOPROTEINS PRODUCED IN PLANTS AND METHODS OF
: TITLE OF INVENTION: THEIR USE
: FILE REFERENCE: 27211/04081
: CURRENT APPLICATION NUMBER: US/11/036,257
: CURRENT FILING DATE: 2005-01-14
: *PRIOR APPLICATION NUMBER: 60/602,562
: PRIOR FILING DATE: 2004-08-18
: PRIOR APPLICATION NUMBER: 60/582,027

```

```

; PRIOR FILING DATE: 2004-06-22
; PRIOR APPLICATION NUMBER: 60/536,486
; PRIOR FILING DATE: 2004-01-14
; NUMBER OF SEQ ID NOS: 173
; SOFTWARE: PatentIn Ver. 3.3
; SEQ ID NO 87
; LENGTH: 226
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: amino acid construct
US-11-036-257-87

```

Query Match	89.1%;	Score 855.5;	DB 7;	Length 226;
Best Local Similarity	85.2%;	Pred. No. 1.5e-75;		
Matches 173;	Conservative 3;	Mismatches 12;	Indels 15;	Gaps 1;
QY	1	MALTFALLVALLVLSCKSSCSVG-----	CDLPQTHSLGSRRTMLLAQMR	45
		: : :		
Db	4	MASLFATFVLVLSLSPSPSPSPSPSPCDLPQTHSLGSRRTMLLAQMR		63
QY	46	RISLFSCLKDRHDFGFPQEEFGNQFOKAETTPVLHEMIQOIFNLFTSKDSSAAMDETLLD		105
Db	64	RISLFSCLKDRHDFGFPQEEFGNQFOKAETTPVLHEMIQOIFNLFTSKDSSAAMDETLLD		123
QY	106	KFYTELTYQQLNDLLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEV		165
Db	124	KFYTELTYQQLNDLLEACVIGVGVTETPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEV		183
QY	166	VRAEIMRSFSLSTNLOESLRKE		188
Db	184	VRAEIMRSFSLSTNLOESLRKE		206

```

RESULT 12
US-11-429-276-386
; Sequence 386, Application US/11429276
; Publication No. US20060194735A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564
; CURRENT APPLICATION NUMBER: US/11/429, 276
; CURRENT FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; PRIOR FILING DATE: 2002-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 386
; LENGTH: 769
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-429-276-386

```

Query Match 89.1%; Score 855.5; DB 7; Length 769;
Best Local Similarity 92.9%; Pred. No. 7e-75;
Matches 170; Conservative 2; Mismatches 10; Indels 1; Gaps 1;
QY 7 LLVALLVLSCKSSCSV-GCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEE 65
Db 2 LLQAFLLLAGFAAKISACDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEE 61
QY 66 FGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOG 125
Db 62 FGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOG 121
QY 126 VGVTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLR 185
Db 122 VGVTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLR 181
QY 186 SKE 188
Db 182 SKE 184

RESULT 13

US-11-429-276-407
; Sequence 407, Application US/11429276
; Publication No. US20060194735A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564
; CURRENT APPLICATION NUMBER: US/11/429,276
; PRIOR FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; PRIOR FILING DATE: 2002-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 407
; LENGTH: 769
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-429-276-407

Query Match 89.1%; Score 855.5; DB 7; Length 769;
Best Local Similarity 92.9%; Pred. No. 7e-75;
Matches 170; Conservative 2; Mismatches 10; Indels 1; Gaps 1;
QY 7 LLVALLVLSCKSSCSV-GCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEE 65
Db 2 LLQAFLLLAGFAAKISACDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEE 61
QY 66 FGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOG 125
Db 62 FGNQFOKAETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOG 121

QY 126 VGVTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLR 185
Db 122 VGVTEPLMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLR 181
QY 186 SKE 188
Db 182 SKE 184

RESULT 14

US-11-429-276-402
; Sequence 402, Application US/11429276
; Publication No. US20060194735A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564
; CURRENT APPLICATION NUMBER: US/11/429,276
; PRIOR FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 402
; LENGTH: 774
; TYPE: PRT
; ORGANISM: Homo sapiens
US-11-429-276-402

Query Match 88.9%; Score 853.5; DB 7; Length 774;
Best Local Similarity 95.5%; Pred. No. 1.e-74;
Matches 168; Conservative 2; Mismatches 5; Indels 1; Gaps 1;

QY 14 LSCKSSCSVG-CDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEEFGNFOK 72
Db 599 LVAAISOALGLCDLPQTHSLGSRRTMLLAQMRISLFSCLKDRHDFGFPQEEFGNFOK 658
QY 73 AETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOGVGTETP 132
Db 659 AETIPVLHEMIQOIFNLFSTKSSAAWDETLDDKFTYELLYQQLNDLEACVIOGVGTETP 718
QY 133 LMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLSKE 188
Db 719 LMKEDSILAVRKYFORITLYLKEKKYSPCAMEVRAEIMRSFSLSTNLQESLSKE 774

RESULT 15

US-11-429-276-1300
; Sequence 1300, Application US/11429276
; Publication No. US20060194735A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Albumin Fusion Proteins
; FILE REFERENCE: PF564

```

; CURRENT APPLICATION NUMBER: US/11/429,276
; CURRENT FILING DATE: 2006-05-08
; PRIOR APPLICATION NUMBER: 10/775,204
; PRIOR FILING DATE: 2004-02-11
; PRIOR APPLICATION NUMBER: PCT/US02/40891
; PRIOR FILING DATE: 2002-12-23
; PRIOR APPLICATION NUMBER: 60/341,811
; PRIOR FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/360,000
; PRIOR FILING DATE: 2002-02-28
; PRIOR APPLICATION NUMBER: 60/378,950
; PRIOR FILING DATE: 2002-05-10
; PRIOR APPLICATION NUMBER: 60/398,008
; PRIOR FILING DATE: 2002-07-24
; PRIOR APPLICATION NUMBER: 60/411,355
; PRIOR FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: 60/414,984
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: 60/417,611
; PRIOR FILING DATE: 2002-10-11
; PRIOR APPLICATION NUMBER: 60/420,246
; PRIOR FILING DATE: 2002-10-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2222
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 1300
; LENGTH: 774
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-11-429-276-1300

```

```

Query Match      88.9%; Score 853.5; DB 7; Length 774;
Best Local Similarity 95.5%; Pred. No. 1.1e-74;
Matches 168; Conservative 2; Mismatches 5; Indels 1; Gaps 1;

QY      14  LSCSSCSVG-CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFOK 72
      |  :|  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB      599  LVASQAALGLCDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFOK 658

QY      73  AETIPVLHEMIQOIFNLSTKDSAAWDETLDDKFTYELTYQQLNDLEACVIGVGTETP 132
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB      659  AETIPVLHEMIQOIFNLSTKDSAAWDETLDDKFTYELTYQQLNDLEACVIGVGTETP 718

QY      133  LMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNLQESLSRSKE 188
      |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||  |||||
DB      719  LMKEDSILAVRKYFORITLYLKEKKYSPCAMEVVRRAEIMRSFSLSTNLQESLSRSKE 774

```

Search completed: October 14, 2006, 08:07:25
Job time : 40 secs

STIC-Biotech/ChemLib

From: Seharaseyon, Jegatheesan
Sent: Thursday, October 12, 2006 7:56 AM
To: STIC-Biotech/ChemLib
Subject: RE: Re:10/650350

Hi,
Sorry. the serial nimber of the case was typed wrong.
It is 10/653350. Therefore, please search SEQ ID NO:1 of 10/653350.

Thanks in advance,
Seyon.

-----Original Message-----

From: STIC-Biotech/ChemLib
Sent: Wednesday, October 11, 2006 4:56 PM
To: Seharaseyon, Jegatheesan
Subject: RE: Re:10/650350

There is no valid CRF for this serial number, please provide us with another valid serial number. Thank you

LEONARD 2-2520

-----Original Message-----

From: Seharaseyon, Jegatheesan
Sent: Wednesday, October 11, 2006 4:51 PM
To: STIC-Biotech/ChemLib
Subject: Re:10/650350

Hi,
Please search SEQ ID NO: 1 of 10/650350 in th commercial databases.
Please provide paper copy of the search results.

Thanks,
SEHARASEYON
Box Rem. 4C70,
Rem 4C61
2-0892.

Searcher: _____
Searcher Phone: _____
Date Searcher Picked up: _____
Date completed: _____
Searcher Prep Time: _____
Online Time: _____

Type of Search
NA# _____ AA#: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure #: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable
STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: _____
WWW/Internet: _____
Other (Specify): _____